Breast malignant eccrine spiradenoma
MONDO:0004420A rare tumor characterized by malignant transformation of an eccrine spiradenoma of the breast.
Also known as: breast malignant spiradenoma, malignant breast eccrine spiradenoma, malignant eccrine spiradenoma of breast, malignant eccrine spiradenoma of the breast, malignant spiradenoma of breast
2916 clinical trials for this condition and its sub-types, 0 tagged with Breast malignant eccrine spiradenoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Showing the 400 most recently updated of 1284 trials in this tab.
-
Off-the-Shelf immune cells target solid tumors
Cure Recruiting nowResearchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …
Phase 1/2 • Sponsor: Ever Supreme Bio Technology Co., Ltd. • Aim: Cure
Last updated Sep 11, 2026 00:00 UTC
-
Can a new drug shrink advanced solid tumors?
Disease control Recruiting nowThis early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Recruiting nowThis study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…
Phase 1/2 • Sponsor: Antares Therapeutics, Inc • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Engineered immune cells take aim at stubborn solid tumors
Disease control Recruiting nowThis trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Can a Twice-Daily pill crack tumors that resist standard treatment?
Disease control Recruiting nowResearchers are testing an experimental oral drug called XNW29016 in adults with advanced solid tumors that have not responded to standard treatment. The trial has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look at early signs of activity…
Phase 1/2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New drug targets cancer spread in first human trial
Disease control Recruiting nowThis early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New pill targets KRAS mutations in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called JAB-23E73, taken as a pill, in adults with advanced solid tumors that have a KRAS alteration. The trial has three parts: first finding a safe dose, then optimizing it, and finally checking if the drug shrinks tumors in certain cancers …
Phase 1/2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New drug targets Hard-to-Treat cancers with missing gene
Disease control Recruiting nowThis study tests a new drug called TNG456, alone or with another drug (abemaciclib), in people with advanced cancers that have lost a gene called MTAP. The trial has two parts: first finding a safe dose, then testing how well it shrinks tumors. Up to 191 adults with lung cancer, …
Phase 1/2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New drug targets cancer DNA in advanced tumors
Disease control Recruiting nowThis early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New drug MDX2001 tested in 285 patients with advanced cancers
Disease control Recruiting nowThis study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…
Phase 1/2 • Sponsor: ModeX Therapeutics, An OPKO Health Company • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Can a Two-Pronged attack shrink advanced solid tumors?
Disease control Recruiting nowThis phase 2 trial is testing whether combining an experimental immunotherapy (MK-2010) with an antibody-drug conjugate (sacituzumab tirumotecan) can help people with advanced solid tumors. The goal is to see if the combination is safe and can shrink or eliminate tumors. Particip…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
First-in-Human trial puts BA1203 to the test against advanced solid tumors
Disease control Recruiting nowResearchers are running a Phase I trial of BA1203, an experimental drug given intravenously every two weeks, in adults with advanced solid tumors that have worsened after standard treatments. The study aims to find out whether BA1203 is safe and tolerable, how the body processes …
Phase 1 • Sponsor: Shandong Boan Biotechnology Co., Ltd • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New drug combo takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests an experimental drug called BSI-082, alone or combined with a standard cancer drug (T-DXd), in 57 adults with advanced or metastatic solid tumors that have not responded to other treatments. The study has two parts: first, finding the safest dose of B…
Phase 1 • Sponsor: Lei Zheng • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New hope for advanced tumors? first human trial of DS-3939a begins
Disease control Recruiting nowThis early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.
Phase 1/2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New combo targets genetic weakness in advanced cancers
Disease control Recruiting nowThis phase 2 trial is testing whether a combination of lenvatinib (a targeted drug) and a PD-1 inhibitor (immunotherapy) can shrink or stop advanced solid tumors that have a specific genetic change called 11q13 amplification. About 60 adults with various cancers like esophageal, …
Phase 2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
Disease control Recruiting nowResearchers are testing a new biological therapy called BI 4060107 in adults with advanced solid tumors that cannot be removed by surgery. The trial is for people who have tried all available treatments and have no other options. The main goal is to find the highest dose that peo…
Phase 1 • Sponsor: AIMEDBIO • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Pulse radiation may supercharge immunotherapy against cancer
Disease control Recruiting nowThis phase 2 trial is testing whether adding a special type of radiation called adaptive pulse radiotherapy to standard immunotherapy can help treat advanced solid tumors. The study will enroll 35 people who are already receiving or planning to receive immune checkpoint inhibitor…
Phase 2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New Antibody-Drug conjugate enters early human trials for advanced cancers
Disease control Recruiting nowThis Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.
Phase 1 • Sponsor: Mabsoft Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New drug TAK-188 aims to unleash immune system against Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new medicine called TAK-188 in adults with advanced solid tumors that have not improved with standard treatments. TAK-188 targets and removes certain cells inside tumors that weaken the immune system, potentially allowing the body to better fight the cancer. Th…
Phase 1/2 • Sponsor: Takeda • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…
Phase 1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
First-in-Human trial tests AK157D1 against advanced solid tumors
Disease control Recruiting nowResearchers are running a first-in-human Phase I trial of AK157D1, an experimental drug given by intravenous infusion, in adults with advanced solid tumors that have worsened after standard treatment or have no standard options left. The study aims to find out whether the drug is…
Phase 1 • Sponsor: Akeso • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New drug combo shows promise for tough cancers
Disease control Recruiting nowThis study tests a new drug called PM54 combined with the immunotherapy pembrolizumab in adults with advanced cancers that have not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing. About 119 par…
Phase 1/2 • Sponsor: PharmaMar • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with specific gene mutation
Disease control Recruiting nowThis study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…
Phase 1/2 • Sponsor: Ensem Therapeutics • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
First-in-Human drug BA1106 put to the test in advanced solid tumors
Disease control Recruiting nowResearchers are running a first-in-human Phase 1 trial of BA1106, an experimental intravenous drug, in adults with advanced solid tumors that have worsened after standard treatments. The main goal is to check safety and tolerability, and to see how the body processes the drug. Pa…
Phase 1 • Sponsor: Shandong Boan Biotechnology Co., Ltd • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
First-in-Human trial tests BA1302 against advanced solid tumors
Disease control Recruiting nowResearchers are running a first-in-human Phase 1 trial of BA1302, an intravenous drug, in adults with advanced solid tumors including melanoma, breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma. The trial has two parts: a dose-escalation phase to find a saf…
Phase 1 • Sponsor: Shandong Boan Biotechnology Co., Ltd • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Engineered IL-2 drug tested against resistant cancers
Disease control Recruiting nowResearchers are testing an engineered interleukin-2 drug called MDNA11 in adults with advanced solid tumors. The trial gives MDNA11 alone or with pembrolizumab, an immune checkpoint inhibitor, to see which doses are safe and how the body processes the drug. It also looks for earl…
Phase 1/2 • Sponsor: Medicenna Therapeutics, Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
First-in-Human drug BA1301 put to the test in advanced solid tumors
Disease control Recruiting nowResearchers are running a first-in-human Phase 1 trial of BA1301, an experimental drug given intravenously every three weeks, in adults with advanced solid tumors that cannot be removed by surgery. The trial enrolls about 70 people aged 18 to 75 whose cancer has progressed after …
Phase 1 • Sponsor: Shandong Boan Biotechnology Co., Ltd • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New drug HY07121 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called HY07121 in 258 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV infusion. The main goals are to check safety, find the right dose, and see if it can shrink tumors. This is an early-stage t…
Phase 1/2 • Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New combo therapy aims to shrink advanced tumors
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers? first human trial launches
Disease control Recruiting nowThis early-stage study is testing a new drug called AT03-65 in 83 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose, while also looking for early signs that the drug might shrink tumors. Part…
Phase 1 • Sponsor: Axcynsis Therapeutics Pte Ltd • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New injection YKYY031 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …
Phase 1 • Sponsor: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New drug targets KRAS mutations in advanced cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called ASP5834 in people with advanced solid tumors that have certain changes in the KRAS gene. The study will first find a safe dose of ASP5834 given alone or with another drug (panitumumab) in people with colorectal cancer. Up to 364…
Phase 1 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New drug combo aims to boost immune system against advanced cancers
Disease control Recruiting nowThis study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New pill targets HER2 cancers in phase 2 trial
Disease control Recruiting nowThis study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Could early radiation prevent spine fractures in cancer patients?
Disease control Recruiting nowThis study tests whether giving radiation early to spine tumors that are not yet painful can prevent serious problems like fractures or spinal cord compression. About 74 adults with cancer that has spread to the spine will receive radiation before symptoms get worse. The goal is …
Phase 1/2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can a new pill help the immune system fight cancer?
Disease control Recruiting nowThis trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…
Phase 1/2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for advanced cancer? experimental drug MHB046C enters human trials
Disease control Recruiting nowThis study tests a new drug called MHB046C in 200 people with advanced solid tumors that no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug intravenously every three weeks.
Phase 1/2 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
First-in-Human antibody MHB118C tested against advanced solid tumors
Disease control Recruiting nowResearchers are testing an experimental antibody injection called MHB118C in adults with advanced solid tumors that have not responded to standard treatments. The trial aims to find out whether the drug is safe, what side effects it causes, and what dose people can tolerate. Part…
Phase 1 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with rare TP53 mutation
Disease control Recruiting nowThis study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …
Phase 1/2 • Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD. • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
BioNTech launches trial of BNT326 for advanced cancers
Disease control Recruiting nowThis study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug, APX-343A, alone or with another cancer drug (pembrolizumab) in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Ab…
Phase 1 • Sponsor: Aptabio Therapeutics, Inc. • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New Dual-Antibody drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…
Phase 1/2 • Sponsor: Ottimo Pharma Limited • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests two experimental drugs, MHB088C and MHB039A, given together by IV to people with advanced solid tumors that no longer respond to standard treatments. The study has two stages: first, finding the safest dose, then checking if the combination can shrink…
Phase 1/2 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New hope for advanced cancer: APR-1051 enters first human trial
Disease control Recruiting nowThis early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…
Phase 1 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New hope for kids with tough cancers: ponatinib trial launches
Disease control Recruiting nowThis study tests the drug ponatinib in children aged 1 to 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the drug can shrink tumors or improve blood counts. About 70 chil…
Phase 1/2 • Sponsor: Incyte Biosciences International Sàrl • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New drug combo tested for tough-to-treat cancers
Disease control Recruiting nowThis study tests an experimental drug called TRK-950 in people with advanced solid tumors or melanoma that has not responded to standard treatments. The first parts check safety and side effects when given alone or with another cancer drug (nivolumab). The final part looks at whe…
Phase 1/2 • Sponsor: Toray Industries, Inc • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Radiation grid meets immune boost: a new attack on stubborn tumors
Disease control Recruiting nowResearchers are testing whether a specialized radiation technique called lattice radiotherapy, combined with PD-1/PD-L1 inhibitor drugs, can safely shrink large tumors in people with advanced solid cancers. The trial enrolls adults whose cancer has progressed after standard treat…
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug targets Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…
Phase 1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
New experimental drug BMS-986500 enters first human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…
Phase 1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Oct 08, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new treatment made from specially engineered cord blood cells (TROP2-CAR-NK cells) in adults with advanced solid tumors that have not responded to standard therapies. The main goal is to find a safe dose and monitor side effects. Up to 54 participan…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Oct 08, 2026 00:00 UTC
-
New hope for advanced cancer? early trial tests MK-3120
Disease control Recruiting nowThis study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 08, 2026 00:00 UTC
-
New cancer drug IACS-6274 enters early human testing
Disease control Recruiting nowThis early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Oct 08, 2026 00:00 UTC
-
New hope: drug may shield kids from virus after transplant
Disease control Recruiting nowThis study tests whether the antiviral drug letermovir can prevent cytomegalovirus (CMV) infection in children and teens who have had a stem cell transplant. About 105 participants aged 2 to 17 will receive letermovir and be monitored for 14 weeks. The goal is to see if the drug …
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Oct 08, 2026 00:00 UTC
-
New drug GEN1119 aims to fight solid tumors that resist standard care
Disease control Recruiting nowThis trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Oct 08, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: drug targets MTAP deletion
Disease control Recruiting nowThis phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Oct 08, 2026 00:00 UTC
-
New cancer drug candidate SHR-4685 enters first human tests
Disease control Recruiting nowThis early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…
Phase 1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Oct 07, 2026 00:00 UTC
-
Can a new oral drug curb Hard-to-Treat cancers?
Disease control Recruiting nowResearchers are testing an experimental oral drug called T-1301 in people with advanced solid tumors or lymphoma that have not responded to standard treatments. The Phase I trial aims to find the highest dose participants can tolerate and the dose best suited for later studies. A…
Phase 1 • Sponsor: Taivex Therapeutics Corporation • Aim: Disease control
Last updated Oct 07, 2026 00:00 UTC
-
New immune drug PHST001 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…
Phase 1 • Sponsor: Pheast Therapeutics • Aim: Disease control
Last updated Oct 07, 2026 00:00 UTC
-
New shot could make cancer treatment easier for patients with advanced tumors
Disease control Recruiting nowThis study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 07, 2026 00:00 UTC
-
Texts vs. manuals: new trial aims to help rural cancer survivors kick the habit
Disease control Recruiting nowThis study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Oct 07, 2026 00:00 UTC
-
Can a nanoparticle deliver chemo more safely to Hard-to-Treat cancers?
Disease control Recruiting nowThis trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…
Phase 1/2 • Sponsor: BrYet US, Inc. • Aim: Disease control
Last updated Oct 07, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat kidney cancer
Disease control Recruiting nowThis early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Oct 07, 2026 00:00 UTC
-
New hope for cancer patients with autoimmune conditions: immune checkpoint inhibitor trial expands access
Disease control Recruiting nowThis study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 07, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with RAS mutations
Disease control Recruiting nowThis study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…
Phase 1/2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Oct 07, 2026 00:00 UTC
-
Experimental drug T-1201 tested against Treatment-Resistant solid tumors
Disease control Recruiting nowResearchers are testing an experimental intravenous drug called T-1201 in adults with advanced solid tumors that have not responded to standard therapy or have no standard treatment left. The main goals are to find the highest dose people can tolerate and the dose best suited for…
Phase 1 • Sponsor: Taivex Therapeutics Corporation • Aim: Disease control
Last updated Oct 04, 2026 00:00 UTC
-
Can radiation start before a cancer biopsy? trial tests a faster path for patients in pain
Disease control Recruiting nowDoctors usually wait for biopsy results before giving radiation, but that wait can be long and painful for patients with advanced cancer. This trial tests whether giving palliative radiation first, before a biopsy confirms cancer, is safe and practical for a carefully selected gr…
Sponsor: David Palma • Aim: Disease control
Last updated Oct 04, 2026 00:00 UTC
-
Drug access bridge: study offers continued treatment for solid tumor patients
Disease control Recruiting nowThis study gives people who are already benefiting from the cancer drugs encorafenib and/or binimetinib in earlier trials continued access to these medicines for up to 5 years. It includes safety monitoring and is open to about 46 participants whose doctors confirm they are still…
Phase 4 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 04, 2026 00:00 UTC
-
Roche offers lifeline: continued cancer drug access for trial patients
Disease control Recruiting nowThis study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Oct 04, 2026 00:00 UTC
-
Can an mRNA therapy supercharge the immune system against cancer?
Disease control Recruiting nowThis trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…
Phase 1/2 • Sponsor: Strand Therapeutics Inc. • Aim: Disease control
Last updated Oct 04, 2026 00:00 UTC
-
New hope for hard-to-treat cancers: combo drug trial launches
Disease control Recruiting nowThis study tests a new drug called mocertatug rezetecan (Mo-Rez) combined with other cancer medicines for people with advanced solid tumors that have stopped responding to standard treatments. About 305 adults will join to see if the combination is safe, tolerable, and effective.…
Phase 1/2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Oct 04, 2026 00:00 UTC
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…
Phase 1/2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Oct 04, 2026 00:00 UTC
-
An oral drug targets a specific gene flaw in Hard-to-Treat tumors
Disease control Recruiting nowResearchers are testing an experimental oral drug called GH56 in people with advanced solid tumors that have lost the MTAP gene. The trial enrolls adults and adolescents whose cancer has progressed after standard treatment or who have no standard options left. The study first fin…
Phase 1 • Sponsor: Suzhou Genhouse Bio Co., Ltd. • Aim: Disease control
Last updated Oct 04, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: experimental drug E303 enters human trials
Disease control Recruiting nowThis early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …
Phase 1 • Sponsor: Samsung Bioepis Co., Ltd. • Aim: Disease control
Last updated Oct 03, 2026 00:00 UTC
-
New pill tested against Hard-to-Treat cancers
Disease control Recruiting nowResearchers are testing a new oral drug called HTL0039732 in people with advanced solid tumors that have not responded to standard treatments. The trial gives the drug alone and in combination with atezolizumab or other approved cancer therapies. The main goals are to find a safe…
Phase 1/2 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Oct 03, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat solid tumors?
Disease control Recruiting nowThis trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…
Phase 1/2 • Sponsor: Hutchmed • Aim: Disease control
Last updated Oct 03, 2026 00:00 UTC
-
Could this pill prevent Chemo-Related bleeding risks?
Disease control Recruiting nowThis study tests an experimental drug, hetrombopag, to see if it can safely raise platelet counts in cancer patients whose platelets drop too low after chemotherapy. About 150 adults with solid tumors (like lung, breast, or colon cancer) will receive either the drug or a placebo …
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Oct 03, 2026 00:00 UTC
-
New flavored drink helps cancer patients keep weight on during treatment
Disease control Recruiting nowThis study tested three flavors of Supportan® drink (Tropical Fruits, Cappuccino, and Pineapple-Coconut) in 123 cancer patients undergoing chemotherapy, radiotherapy, immunotherapy, or targeted therapy. Patients drank two bottles daily for four weeks alongside their normal diet. …
Sponsor: Fresenius Kabi Taiwan Ltd. • Aim: Disease control
Last updated Oct 03, 2026 00:00 UTC
-
New shot shows promise against tough cancers
Disease control Recruiting nowThis study tests a new drug called IPN60300 in adults with advanced solid tumors that have spread or not responded to standard treatments. The goal is to find the best dose and check if it is safe and shrinks tumors. All participants get the drug by injection, and the study invol…
Phase 1/2 • Sponsor: Ipsen • Aim: Disease control
Last updated Oct 03, 2026 00:00 UTC
-
Can a Dual-Pronged antibody outsmart advanced solid tumors?
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called SI-B036, a bispecific antibody designed to target cancer cells in a unique way. The study involves adults with locally advanced or metastatic head and neck tumors or other solid tumors. The main goals are to assess the…
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Oct 03, 2026 00:00 UTC
-
New drug combo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…
Phase 1 • Sponsor: Exelixis • Aim: Disease control
Last updated Oct 03, 2026 00:00 UTC
-
Engineered NK cells take on tough cancers in first human test
Disease control Recruiting nowThis early-phase trial tests a new type of immune cell therapy for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own natural killer (NK) cells that have been genetically modified to produce IL-15, a protein that hel…
Early phase 1 • Sponsor: Genovn Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Oct 02, 2026 00:00 UTC
-
New hope for advanced cancer: first human trial of FP008 begins
Disease control Recruiting nowThis early-stage study tests a new drug called FP008 in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether…
Phase 1 • Sponsor: Zhuhai Fapon Biopharma Co., Ltd. • Aim: Disease control
Last updated Oct 02, 2026 00:00 UTC
-
New drug could protect children with cancer from chemo side effects
Disease control Recruiting nowThis study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.
Phase 2 • Sponsor: Spectrum Pharmaceuticals, Inc • Aim: Disease control
Last updated Oct 02, 2026 00:00 UTC
-
New drug cocktail aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing whether a new drug called ZEN003694, when added to the chemotherapy capecitabine, is safe for people with advanced solid tumors that have spread or can't be removed by surgery. About 30 participants will receive the combination to find the best d…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 01, 2026 00:00 UTC
-
New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…
Phase 1 • Sponsor: Duboce Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Oct 01, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers? first human trial of AUBE00 begins
Disease control Recruiting nowThis early-stage study tests a new drug, AUBE00, in about 90 to 130 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have a spec…
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Oct 01, 2026 00:00 UTC
-
New cancer drug BI 3810944 enters first human tests
Disease control Recruiting nowThis early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Oct 01, 2026 00:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control Recruiting nowThis study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 30, 2026 00:00 UTC
-
New hope for cancer patients: experimental drug aims to stop dangerous blood clots
Disease control Recruiting nowThis study tests an experimental drug, REGN7508, to see if it works better than the standard blood thinner apixaban for treating and preventing blood clots in people with cancer. The trial will include about 1,600 participants with or without cancer who have deep vein thrombosis …
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 30, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 30, 2026 00:00 UTC
-
New pill shows promise in early cancer trial
Disease control Recruiting nowThis early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 30, 2026 00:00 UTC
-
New cancer drug targets two proteins at once in early trial
Disease control Recruiting nowThis early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 30, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 30, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers? early trial launches for BHV-1510
Disease control Recruiting nowThis early-phase trial is testing a new drug called BHV-1510, either alone or with another drug (cemiplimab), in 500 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if the drug can shrink tumors. Because …
Phase 1/2 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Sep 30, 2026 00:00 UTC
-
Can a simple infusion stop Immunotherapy's worst side effects?
Disease control Recruiting nowThis study tests whether giving siltuximab alongside restarting immunotherapy can prevent severe immune-related side effects in people with advanced cancer. About 40 adults who previously had serious side effects from immunotherapy will receive siltuximab to calm the immune syste…
Phase 2 • Sponsor: Yuanquan Yang • Aim: Disease control
Last updated Sep 30, 2026 00:00 UTC
-
New immune therapy shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called RPTR-1-201 in 150 adults with advanced solid tumors that cannot be cured with standard treatments. The drug works by helping the body's immune cells attack cancer. The study aims to find the safest dose and see if the drug shrinks tu…
Phase 1/2 • Sponsor: Repertoire Immune Medicines • Aim: Disease control
Last updated Sep 30, 2026 00:00 UTC
-
New liposome drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…
Phase 1 • Sponsor: HighField Biopharmaceuticals Corporation • Aim: Disease control
Last updated Sep 30, 2026 00:00 UTC
-
Can breast radiation be compressed to one week without hurting cosmetic results?
Disease control Recruiting nowResearchers are testing whether a one-week course of partial breast irradiation works as well as a three-week course in women with low-risk early breast cancer who had breast-conserving surgery. The trial enrolls about 818 women and randomly assigns them to either 26 Gy in 5 trea…
Sponsor: Fudan University • Aim: Disease control
Last updated Sep 27, 2026 00:00 UTC
-
New chemo injection targets tumors directly in early trial
Disease control Recruiting nowThis early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…
Phase 1 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated Sep 27, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug IMC-002 enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…
Phase 1 • Sponsor: ImmuneOncia Therapeutics Inc. • Aim: Disease control
Last updated Sep 27, 2026 00:00 UTC
-
New cancer drug enters early human testing for advanced solid tumors
Disease control Recruiting nowThis early-phase study tests a new drug called GSK5533524, alone or with other cancer treatments, in adults with advanced solid tumors that have stopped responding to standard therapies. The main goals are to find a safe dose and see if the drug can shrink tumors or slow cancer g…
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 27, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study tests a new drug called BH3120, alone or with pembrolizumab, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 245 p…
Phase 1 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Sep 27, 2026 00:00 UTC
-
Cancer-Fighting virus injected into tumors shows promise in early trial
Disease control Recruiting nowThis early-phase study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…
Phase 1 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated Sep 27, 2026 00:00 UTC
-
Two-Payload antibody aims at Hard-to-Treat solid tumors
Disease control Recruiting nowResearchers are testing an experimental drug called IBI3020 in adults with solid tumors that have spread or cannot be removed by surgery. IBI3020 is an antibody-drug conjugate that targets the CEACAM5 protein on tumor cells and delivers two different payloads. The main goals are …
Phase 1 • Sponsor: Fortvita Biologics (USA)Inc. • Aim: Disease control
Last updated Sep 27, 2026 00:00 UTC
-
New drug NEOK001 targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …
Phase 1 • Sponsor: NEOK Bio, Inc. • Aim: Disease control
Last updated Sep 27, 2026 00:00 UTC
-
First-in-Human trial tests IBI3001 against advanced solid tumors
Disease control Recruiting nowResearchers are running a Phase 1 trial of IBI3001, an intravenous drug, in adults with unresectable, locally advanced or metastatic solid tumors. The study aims to find the highest dose people can tolerate and the dose to use in later trials. Participants receive IBI3001 by infu…
Phase 1 • Sponsor: Fortvita Biologics (USA)Inc. • Aim: Disease control
Last updated Sep 27, 2026 00:00 UTC
-
New Antibody-Drug conjugate KIVU-107 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…
Phase 1 • Sponsor: Kivu Bioscience Inc. • Aim: Disease control
Last updated Sep 26, 2026 00:00 UTC
-
New antibody drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new drug called CDR404 in up to 42 adults with advanced solid tumors that have a specific marker (MAGE-A4) and tissue type (HLA-A*02:01). The drug is designed to help the body's immune T-cells find and attack cancer cells. The main goals are to chec…
Phase 1 • Sponsor: CDR-Life AG • Aim: Disease control
Last updated Sep 26, 2026 00:00 UTC
-
New drug targets cancer enzyme in early human trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called MTI-301 in 42 adults with advanced solid cancers that have spread or can't be removed and haven't responded to standard treatments. The drug blocks an enzyme called SCD1, which some cancers use to grow and spread. The main goals…
Phase 1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 26, 2026 00:00 UTC
-
Can a new pill shrink advanced solid tumors?
Disease control Recruiting nowThis trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…
Phase 1/2 • Sponsor: Orion Corporation, Orion Pharma • Aim: Disease control
Last updated Sep 26, 2026 00:00 UTC
-
New drug RC288 targets Hard-to-Treat tumors in early trial
Disease control Recruiting nowThis study tests a new drug called RC288 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 326 adults aged 18 to 75 with good overall health will take …
Phase 1/2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Sep 25, 2026 00:00 UTC
-
New cancer drug DXC014 enters first human tests
Disease control Recruiting nowThis early-stage study tests a new drug called DXC014 in about 150 people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors.…
Phase 1 • Sponsor: Hangzhou DAC Biotechnology Co., Ltd. • Aim: Disease control
Last updated Sep 25, 2026 00:00 UTC
-
Experimental biologic AWT020 put to the test in Hard-to-Treat cancers
Disease control Recruiting nowResearchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…
Phase 1 • Sponsor: Anwita Biosciences • Aim: Disease control
Last updated Sep 25, 2026 00:00 UTC
-
MRNA injection aims to turn cold tumors hot
Disease control Recruiting nowResearchers are testing an experimental mRNA injection called ABO2011 in adults with advanced solid tumors that have worsened after standard treatment. The injection delivers genetic instructions for interleukin-12, a protein that can stir up an immune response, directly into the…
Phase 1/2 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: Disease control
Last updated Sep 25, 2026 00:00 UTC
-
New hope for advanced cancers: experimental drug ACR-2316 enters first human trial
Disease control Recruiting nowThis early-stage trial tests an experimental drug called ACR-2316 in 100 people with advanced solid tumors that have spread or come back. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. It is for patients who have had up to 3 pr…
Phase 1/2 • Sponsor: Acrivon Therapeutics • Aim: Disease control
Last updated Sep 25, 2026 00:00 UTC
-
Can a Tumor-Directed injection shrink Hard-to-Treat cancers?
Disease control Recruiting nowThis early-stage trial tests an investigational drug called HP007, given as an injection directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments or have come back. The main goals are to check the drug's safety, find the right dose…
Phase 1 • Sponsor: Parr Biotechnology (Hebei) Co., Ltd. • Aim: Disease control
Last updated Sep 25, 2026 00:00 UTC
-
Can a new drug shrink tumors that resist other treatments?
Disease control Recruiting nowThis trial tests an experimental drug called FH-006 in 150 people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if FH-006 is safe, tolerable, and can shrink tumors. Researchers will measure how the drug moves through the body and …
Phase 1/2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Sep 25, 2026 00:00 UTC
-
Cancer patients get continued access to promising drugs in new safety trial
Disease control Recruiting nowThis study offers long-term treatment with nivolumab and other cancer therapies to 1,500 patients who previously benefited from Bristol-Myers Squibb trials. The main goal is to monitor safety and side effects over time. Participants must have had a good response in their earlier …
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 25, 2026 00:00 UTC
-
New enzyme shot takes aim at Hard-to-Treat tumors
Disease control Recruiting nowThis trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…
Phase 1/2 • Sponsor: Onchilles Pharma Inc • Aim: Disease control
Last updated Sep 25, 2026 00:00 UTC
-
New drug KIVU-305 takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…
Phase 1 • Sponsor: Kivu Bioscience Inc. • Aim: Disease control
Last updated Sep 24, 2026 00:00 UTC
-
Can your Cancer's genes pick the right drug? TAPUR study aims to find out
Disease control Recruiting nowThe TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…
Phase 2 • Sponsor: American Society of Clinical Oncology • Aim: Disease control
Last updated Sep 24, 2026 00:00 UTC
-
Experimental cocktail targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called lunresertib, alone or combined with two other experimental drugs (RP-3500 and Debio 0123), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for earl…
Phase 1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Sep 24, 2026 00:00 UTC
-
Can a pill turn on genes that stop cancer? new trial begins
Disease control Recruiting nowThis early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 24, 2026 00:00 UTC
-
New drug SLV-154 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called SLV-154 in about 70 people with advanced solid tumors (like head and neck, lung, breast, or ovarian cancer) that have spread. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs …
Phase 1 • Sponsor: Solve Therapeutics • Aim: Disease control
Last updated Sep 24, 2026 00:00 UTC
-
New hope for advanced cancers: experimental drug EIK1005 enters human trials
Disease control Recruiting nowThis study tests a new drug called EIK1005, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug shrinks tumors. About 160 adults with certain cancer types…
Phase 1/2 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Sep 24, 2026 00:00 UTC
-
Engineered herpes virus takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…
Phase 1/2 • Sponsor: Virogin Biotech Ltd. • Aim: Disease control
Last updated Sep 24, 2026 00:00 UTC
-
New pill NP-101 tested in patients with Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug HMPL-A580 enters human trials
Disease control Recruiting nowThis early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…
Phase 1/2 • Sponsor: Hutchmed • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Poop pills? stool transplants may ease immunotherapy side effects
Disease control Recruiting nowThis early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody combo shows promise in early cancer trial
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…
Phase 1/2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug cocktail aims to outsmart advanced cancers
Disease control Recruiting nowThis early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New bispecific antibody D3L-002 enters first human trial for Hard-to-Treat cancers
Disease control Recruiting nowThis Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…
Phase 1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug DS3610a enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cancer drug YL217 enters first human tests
Disease control Recruiting nowThis early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…
Phase 1 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…
Phase 1/2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
First-in-Human trial asks whether HG381 is safe and tolerable in advanced solid tumors
Disease control Recruiting nowResearchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…
Phase 1 • Sponsor: HitGen Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New cancer drug GI-108 enters human trials for advanced tumors
Disease control Recruiting nowThis study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …
Phase 1/2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy takes on advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…
Phase 1/2 • Sponsor: Hefei Xinzhu Biological Technology Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug cocktail aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…
Phase 1/2 • Sponsor: Wigen Biomedicine Technology (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental injection SHR-7787 put to the test against advanced solid tumors
Disease control Recruiting nowResearchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…
Phase 1/2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a pill shrink Hard-to-Treat ovarian tumors?
Disease control Recruiting nowResearchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…
Phase 1/2 • Sponsor: Heronova Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
DNA-Guided immunotherapy trial aims to match drug to tumor
Disease control Recruiting nowThis study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…
Phase 2 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill shows promise in early trial for tough cancers
Disease control Recruiting nowThis early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…
Phase 1/2 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a smart drug deliver a toxic payload directly to cancer cells?
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…
Phase 1 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can steroids help cancer patients resume a promising therapy?
Disease control Recruiting nowThis study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug DXP-106 enters early human testing
Disease control Recruiting nowThis early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…
Phase 1 • Sponsor: Singlomics Biopharmaceuticals Zhuhai Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug QLC5508 enters first human safety tests
Disease control Recruiting nowThis early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…
Phase 1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug ART6043 enters human trials for advanced tumors
Disease control Recruiting nowThis study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…
Phase 1/2 • Sponsor: Artios Pharma Ltd • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: first human trial of BGB-58067 begins
Disease control Recruiting nowThis early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Could a simple mask help cancer patients avoid a breathing tube?
Disease control Recruiting nowThis study tests whether a non-invasive ventilation mask (NIPPV) can reduce the need for intubation in cancer patients with respiratory failure. Researchers will compare NIPPV plus standard oxygen therapy to standard oxygen therapy alone in 256 participants. The goal is to see if…
Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug BG-C477 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a radioactive 'Smart Bomb' target tough tumors?
Disease control Recruiting nowResearchers are testing an experimental radioactive drug called 177Lu-FAP-VG11 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attach to a protein called FAP, which is found on many tumor cells. This early …
Early phase 1 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…
Phase 1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Experimental biologic M1-c6v1 put to the test in Hard-to-Treat solid tumors
Disease control Recruiting nowResearchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…
Phase 1 • Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Triple-Action antibody takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Narrow beams, big hope: new radiation approach tested for skin tumors
Disease control Recruiting nowThis study tests a new radiation method called minibeam therapy for people with skin or soft tissue tumors that have come back or spread. The treatment uses a special device to split a wide radiation beam into many tiny beams, which may reduce damage to healthy tissue. The goal i…
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug SKB118 aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…
Phase 1/2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Experimental biological therapy VRT106 put to the test in advanced solid tumors
Disease control Recruiting nowResearchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…
Phase 1 • Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New cancer drug KK2269 enters first human tests
Disease control Recruiting nowThis early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…
Phase 1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug aims to reignite immune attack on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called IL12-L19L19 (Dodekin) in 80 adults with advanced or metastatic solid tumors that have stopped responding to standard immunotherapy. The drug combines an antibody with an immune-boosting protein to target and attack cancer cells.…
Phase 1 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug FORX-428 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …
Phase 1 • Sponsor: FoRx Therapeutics AG • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug SHR-4610 tested in patients with Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…
Phase 1/2 • Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a new pill shrink Hard-to-Treat tumors?
Disease control Recruiting nowThis trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…
Phase 1/2 • Sponsor: Lamassu Bio Inc • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody GEN1079 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
One shot of radiation: can a single dose replace weeks of breast cancer treatment?
Disease control Recruiting nowResearchers are testing whether a single, concentrated dose of radiation to the tumor site can replace the usual weeks of daily radiation after breast-conserving surgery. The trial enrolls 250 women with early-stage, low-risk breast cancer that has not spread to lymph nodes. Doct…
Sponsor: National Institute of Oncology, Hungary • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug SGT003 put to the test against Hard-to-Treat solid tumors
Disease control Recruiting nowResearchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…
Phase 1/2 • Sponsor: Beijing Sungen Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New targeted drug enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…
Phase 1 • Sponsor: Adcendo ApS • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New cancer drug AGX101 enters human trials for advanced tumors
Disease control Recruiting nowThis early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…
Phase 1 • Sponsor: Angiex, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
BioNTech launches first human test of BNT317 against advanced cancers
Disease control Recruiting nowThis early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New cancer drug FID-022 enters first human trial
Disease control Recruiting nowThis early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …
Phase 1 • Sponsor: Fulgent Pharma LLC. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a Two-Drug combo reawaken the immune system against resistant cancers?
Disease control Recruiting nowThis trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …
Phase 1/2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Experimental pill GS-1206 takes aim at Hard-to-Treat solid tumors
Disease control Recruiting nowThis study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New radioactive drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new radioactive drug, 177Lu-INN805, in 10 people with advanced solid tumors (like head & neck, lung, breast, or sarcoma) that haven't responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…
Early phase 1 • Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New antibody drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for tough cancers: experimental drug IMGS-001 enters human trials
Disease control Recruiting nowThis early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…
Phase 1 • Sponsor: ImmunoGenesis • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with brain spread
Disease control Recruiting nowThis early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …
Phase 1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New pill CT7439 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called CT7439, taken as a capsule, in about 50 people with solid tumors that have spread or cannot be removed. The study will first test CT7439 alone, then in combination with other cancer treatments. The main goals are to ch…
Phase 1/2 • Sponsor: Carrick Therapeutics Limited • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug SKB565 aims to fight advanced solid tumors
Disease control Recruiting nowThis study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…
Phase 1/2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug VBC101 targets tough cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called VBC101 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer-related targets (EGFR and cMET) and deliver a toxic payload directly to cancer cells. The s…
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New pill targets rare cancer gene in 30-Patient trial
Disease control Recruiting nowThis phase 2 trial tests an oral drug called lirafugratinib in 30 adults with advanced solid tumors (excluding bile duct cancer) that have an FGFR2 gene fusion or rearrangement. Participants take the drug regularly and visit the clinic for checkups. The main goal is to see if the…
Phase 2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for tough cancers: experimental drug IPN01203 enters human trials
Disease control Recruiting nowThis study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…
Phase 1/2 • Sponsor: Ipsen • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug targets hard-to-treat cancers with missing MTAP gene
Disease control Recruiting nowThis early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…
Phase 1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for advanced cancers? first human trial of DS5361b begins
Disease control Recruiting nowThis early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug IMA402 targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.
Phase 1/2 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug targets two cancer proteins in advanced tumors
Disease control Recruiting nowThis trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Fertility shield: new trial tests triptorelin to save ovaries during chemo
Disease control Recruiting nowThis phase 3 trial tests whether the drug triptorelin can protect the ovaries of adolescents and young adults with cancer who are receiving chemotherapy. Chemotherapy can damage the ovaries, making it hard or impossible to get pregnant later. Triptorelin temporarily pauses ovaria…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Experimental CAR t therapy takes on solid tumors in first human trial
Disease control Recruiting nowThis early-phase trial is testing a new immunotherapy called LEU011 for people with advanced solid tumors that have not responded to other treatments. LEU011 uses the patient's own immune cells, modified to better recognize and attack tumor cells. The study aims to find a safe do…
Phase 1/2 • Sponsor: Leucid Bio • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Could simple Over-the-Counter drugs supercharge cancer immunotherapy?
Disease control Recruiting nowThis study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…
Phase 2 • Sponsor: Val Adams • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill takes on advanced cancers in first human test
Disease control Recruiting nowThis early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…
Phase 1 • Sponsor: Groovy Medicine (Hangzhou) Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a Custom-Made immune cell vaccine turn the tide against solid tumors?
Disease control Recruiting nowThis trial tests a personalized approach to treating advanced solid tumors. Doctors take a patient's own immune cells, train them to recognize that patient's specific cancer mutations, and inject them back under the skin. The goal is to see if these customized cells can safely tr…
Sponsor: ZSky Biotech Inc • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
A new care pathway aims to get cancer surgery patients home safer and faster
Disease control Recruiting nowThis large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…
Sponsor: Regional Specialist Hospital in Wroclaw • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can engineered red blood cells fight cancer? new trial launches
Disease control Recruiting nowThis early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…
Early phase 1 • Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Engineered virus targets Hard-to-Treat cancers from the inside
Disease control Recruiting nowThis study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…
Phase 2 • Sponsor: Tianjin First Central Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Tailored rehab program aims to help young adults reclaim life after cancer
Disease control Recruiting nowThis trial tests a 16-week rehabilitation program called YATAC, designed specifically for young adults aged 18–39 who have or have had cancer. The program includes physical activity, mental health support, nutrition advice, and help with education or work. Researchers want to see…
Sponsor: University of Aarhus • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Exercise after cancer: could resistance training rebuild bodies?
Disease control Recruiting nowThis study tests whether a closely supervised resistance training program can improve functional mobility, body composition, and strength in people who have been treated for cancer. Participants aged 20 to 89 will follow a structured exercise regimen during or after their cancer …
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Zapping resistant tumors may extend life of cancer drugs
Disease control Recruiting nowThis study tests whether adding a precise local treatment—like focused radiation or ablation—can help people whose cancer has a few new or growing spots while on standard therapy. Participants continue their usual medication while the resistant tumors are treated directly. The go…
Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New cocktail of old drugs takes on advanced cancers
Disease control Recruiting nowThis Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…
Phase 2 • Sponsor: Sarcoma Oncology Research Center, LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New experimental drug SIM0613 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…
Phase 1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New biologic JLM019 enters human testing for advanced cancers
Disease control Recruiting nowThis early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …
Phase 1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Chilling out to fight cancer: cold therapy meets immunotherapy in new trial
Disease control Recruiting nowThis early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Telehealth program aims to help cancer survivors kick bad habits
Disease control Recruiting nowThis study tests a telehealth program to help cancer survivors quit smoking, lose weight, and get more active. About 1500 participants will either get coaching sessions or just information. The goal is to see which approach works better for improving long-term health.
Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New radiation 'Lattice' method paired with immunotherapy shows promise for tough cancers
Disease control Recruiting nowThis phase 2 trial tests a new radiation technique called lattice radiation therapy (LRT) combined with immunotherapy in 30 people with advanced solid tumors that have not responded to standard treatments. LRT delivers high doses of radiation to small spots inside the tumor while…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental virus therapy takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …
Phase 1 • Sponsor: KaliVir Immunotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
AI meets skin cancer screening: can algorithms improve diagnosis?
Diagnosis Recruiting nowThis study examines how teledermoscopy, where skin lesion images are sent for remote review, affects referral patterns and skin cancer detection in clinical practice. It also tests whether artificial intelligence support tools improve diagnostic accuracy for doctors assessing the…
Sponsor: Region Skane • Aim: Diagnosis
Last updated Oct 17, 2026 08:00 UTC
-
Radioactive tracer homes in on a protein tumors use to survive low oxygen
Diagnosis Recruiting nowResearchers are testing a PET/CT scan that uses a radioactive tracer called 68Ga-CAIX to detect solid tumors. The tracer binds to CAIX, a protein that many solid tumors produce when oxygen is scarce. The study enrolls about 100 adults with suspected or confirmed solid tumors, inc…
Sponsor: Zhongnan Hospital • Aim: Diagnosis
Last updated Oct 15, 2026 00:00 UTC
-
New breast imaging could make biopsies more accurate
Diagnosis Recruiting nowThis study tests whether molecular breast imaging (MBI) can guide biopsies for breast abnormalities that are hard to see on ultrasound or mammography. About 70 women with a prior MBI finding that turned out to be benign will undergo a new MBI-guided biopsy procedure. The goal is …
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Oct 07, 2026 00:00 UTC
-
New imaging agent aims to light up hidden tumors
Diagnosis Recruiting nowThis early-stage study will test a new radioactive tracer called [89Zr]DFO-YS5 in 40 people with nerve sheath tumors, bladder cancer, or other advanced solid tumors. The tracer is designed to bind to cancer cells and show up on PET scans, potentially making tumors easier to see. …
Phase 1 • Sponsor: Robert Flavell, MD, PhD • Aim: Diagnosis
Last updated Oct 03, 2026 00:00 UTC
-
New probe lights up PD-L1 across tumors
Diagnosis Recruiting nowResearchers are testing a radionuclide probe that targets PD-L1, a protein some tumors use to evade the immune system. Adults with solid tumors such as lung, cervical, breast, melanoma, or gastrointestinal cancers receive the probe and then undergo whole-body PET/CT imaging. The …
Phase 2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Oct 01, 2026 00:00 UTC
-
A tracer that lights up immune attack: can scans predict who responds to cancer immunotherapy?
Diagnosis Recruiting nowResearchers are testing a radioactive tracer called 18F-G1 that binds to granzyme B, a protein released when immune cells attack tumors. Adults with solid tumors or blood cancers who are about to start immunotherapy receive an injection of 18F-G1 and then undergo PET/CT scans. Th…
Sponsor: Peking University First Hospital • Aim: Diagnosis
Last updated Sep 30, 2026 00:00 UTC
-
One magnetic tracer could mark breast tumors and lymph nodes in a single step
Diagnosis Recruiting nowResearchers test whether a magnetic tracer called Magtrace can do two jobs at once during breast-conserving surgery: outline the area of breast tissue to remove and help find the sentinel lymph node in the armpit. The study enrolls about 35 patients with breast cancer who need br…
Sponsor: King Faisal Specialist Hospital & Research Center • Aim: Diagnosis
Last updated Sep 30, 2026 00:00 UTC
-
New scan could reveal how well your immune system fights cancer
Diagnosis Recruiting nowThis study tests an experimental imaging agent (89Zr-DFO-REGN5054) that may help visualize immune cells called CD8+ T cells in tumors. About 50 people with advanced solid cancers will receive the imaging agent along with the immunotherapy drug cemiplimab. The main goal is to chec…
Phase 1 • Sponsor: Regeneron Pharmaceuticals • Aim: Diagnosis
Last updated Sep 23, 2026 00:00 UTC
-
Simple blood test could spot cancer earlier in symptomatic patients
Diagnosis Recruiting nowThis study is testing two new blood tests designed to help doctors detect cancer in people who have symptoms that might be cancer. The study will involve 1,650 adults aged 45 and older who are already undergoing medical tests for possible cancer. The goal is to see how well these…
Sponsor: Harbinger Health • Aim: Diagnosis
Last updated Sep 23, 2026 00:00 UTC
-
Glowing dye could light up leftover cancer cells at surgery edges
Diagnosis Recruiting nowResearchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…
Sponsor: Erasmus Medical Center • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Can a new PET tracer reveal hidden tau in the brain?
Diagnosis Recruiting nowThis study tests whether a radioactive tracer called 18F-S16/T807 can help diagnose tau-related brain diseases. Tau is a protein that builds up abnormally in conditions like Alzheimer's and other neurodegenerative disorders. Researchers will give 500 adults a single injection of …
Sponsor: Tianjin Medical University • Aim: Diagnosis
Last updated Sep 10, 2026 00:00 UTC
-
Can a brain scan reveal the hidden amyloid behind neurodegenerative disease?
Diagnosis Recruiting nowThis study tests whether PET/CT scans using two radioactive tracers, 18F-92/AV45 and 11C-PIB, can detect beta amyloid buildup in the brain. Researchers will enroll 500 adults with suspected or known neurodegenerative diseases linked to amyloid. Each participant receives one injec…
Sponsor: Tianjin Medical University • Aim: Diagnosis
Last updated Sep 10, 2026 00:00 UTC
-
New scan could reveal hidden cancers in PD-L1 patients
Diagnosis Recruiting nowThis study is testing a special type of PET/CT scan that looks for a protein called PD-L1 on cancer cells. The goal is to see if this scan can find tumors and their spread more accurately than standard imaging. About 500 adults with suspected or known PD-L1-related cancers will r…
Sponsor: Tianjin Medical University • Aim: Diagnosis
Last updated Sep 10, 2026 00:00 UTC
-
A new imaging tracer may reveal hidden nerve injuries
Diagnosis Recruiting nowThis trial tests whether an injected tracer called HED, seen on PET/CT or MRI scans, can help diagnose diseases of the sympathetic nervous system, the part of the body that controls automatic responses like heart rate and blood pressure. Researchers will scan 500 adults who have …
Sponsor: Tianjin Medical University • Aim: Diagnosis
Last updated Sep 10, 2026 00:00 UTC
-
Can a quicker MRI spot breast cancer sooner? new study recruits 400 High-Risk women
Diagnosis Recruiting nowThis study enrolls 400 women at high risk for breast cancer to see if a shorter, abbreviated MRI scan works as well as a full-length MRI for early detection. Participants will get MRI scans every 6 months. The goal is to develop faster, personalized screening that could make regu…
Sponsor: University of Chicago • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
Diagnosis Recruiting nowThis study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Could a simple blood test replace invasive tissue biopsies for cancer genetics?
Diagnosis Recruiting nowThis study compares a blood test (liquid biopsy) to the standard tissue biopsy for finding genetic changes in advanced solid tumors. The goal is to see if the liquid biopsy can accurately detect the same genetic alterations as the tissue sample. If it works, patients might avoid …
Sponsor: Centre Antoine Lacassagne • Aim: Diagnosis
Last updated Jul 22, 2026 00:00 UTC
-
Simple blood test aims to spot multiple cancers early
Diagnosis Recruiting nowThis study collects blood samples from healthy people, those with benign diseases, and cancer patients to develop a multi-analyte blood test. The test looks for DNA methylation markers that may indicate the presence of various cancers, especially liver cancer. Researchers aim to …
Sponsor: Helio Genomics • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
New scan technique could sharpen tumor targeting during radiation
Diagnosis Recruiting nowThis study tests whether a special CT scan with contrast dye can give clearer images of tumors during radiation therapy. Twenty adults with advanced cancer will receive the extra scan alongside their standard treatment. The goal is to see if this approach is feasible and improves…
Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New PET tracer could spot hidden cancers
Diagnosis Recruiting nowThis study is testing a new radioactive imaging agent called 68Ga-DOTA-EphA2 to help see certain proteins on cancer cells during PET/CT scans. The goal is to improve how doctors detect and monitor malignant tumors. About 30 adults with suspected or confirmed cancer will receive t…
Sponsor: First Hospital of China Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 12:34 UTC
-
New shot could stop deadly clots in cancer patients
Prevention Recruiting nowThis phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Prevention
Last updated Oct 15, 2026 00:00 UTC
-
Can a new drug shield nerves from Chemotherapy's side effects?
Prevention Recruiting nowThis phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…
Phase 2 • Sponsor: Sironax USA, Inc. • Aim: Prevention
Last updated Oct 11, 2026 00:00 UTC
-
Which laxative best prevents constipation when cancer patients start opioids?
Prevention Recruiting nowMany people with advanced cancer take opioid pain medicines, which often cause constipation. This trial compares two laxatives, macrogol/electrolytes and magnesium hydroxide, to see which works better at preventing constipation when opioids are started. Adults with advanced cance…
Phase 4 • Sponsor: Amsterdam UMC, location VUmc • Aim: Prevention
Last updated Oct 07, 2026 00:00 UTC
-
Can a gentler blood thinner shield cancer patients from new clots?
Prevention Recruiting nowCancer patients with a central catheter can develop a blood clot in the upper arm. After at least three months of standard blood-thinning treatment, this trial tests whether switching to a lower, preventive dose of apixaban can stop new clots from forming. Participants stay on th…
Phase 4 • Sponsor: Ottawa Hospital Research Institute • Aim: Prevention
Last updated Sep 23, 2026 00:00 UTC
-
Cheap statin could slash deadly clot risk in cancer patients
Prevention Recruiting nowThis study tests whether taking a daily statin (rosuvastatin) for one year can safely prevent life-threatening blood clots in people with cancer. Current clot-preventing drugs raise bleeding risks, so a safer option is needed. The trial will enroll 4,000 adults with newly diagnos…
Phase 4 • Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Digital therapy aims to tame the fear that haunts cancer survivors
Symptom relief Recruiting nowThis trial tests a blended e-health program designed to help women with breast or gynecologic cancer cope with fear of their cancer returning or worsening. The program combines remote group sessions with online modules that teach skills to manage unhelpful thoughts and promote he…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Oct 17, 2026 08:00 UTC
-
Can exercise during cancer treatment keep patients stronger?
Symptom relief Recruiting nowResearchers at McMaster University are testing whether a structured exercise and education program helps people with cancer stay physically active during treatment. The trial enrolls 129 adults receiving cancer treatment of any type or stage. Participants join one of three groups…
Phase 2 • Sponsor: McMaster University • Aim: Symptom relief
Last updated Oct 17, 2026 08:00 UTC
-
Cactus extract could zap cancer pain in new trial
Symptom relief Recruiting nowThis early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…
Phase 1 • Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Symptom relief
Last updated Oct 17, 2026 08:00 UTC
-
Can an AI chatbot ease the aftermath of cancer?
Symptom relief Recruiting nowThis study tests whether an AI-powered chatbot can help young adult cancer survivors manage ongoing symptoms like fatigue, anxiety, and sleep problems. Participants aged 18-39 who have finished primary cancer treatment will interact with the chatbot to get tailored educational su…
Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief
Last updated Oct 17, 2026 00:00 UTC
-
3,000-Patient study tracks Anti-Nausea drug in routine cancer care
Symptom relief Recruiting nowResearchers in China are observing how well the approved medicine HR20013 prevents nausea and vomiting caused by anticancer treatment. The study plans to follow about 3,000 adults with any tumor type who receive HR20013 as part of their usual care at more than 30 hospitals. It wi…
Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Oct 16, 2026 00:00 UTC
-
Sniffing away sickness: essential oils tested for chemo nausea
Symptom relief Recruiting nowThis trial explores whether inhaling essential oils like peppermint, lavender, or ginger can help reduce nausea and anxiety in cancer patients receiving chemotherapy infusions. Current anti-nausea drugs often cause constipation and fatigue, so researchers are looking for gentler …
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Oct 16, 2026 00:00 UTC
-
Can AI songwriting calm cancer anxiety better than music alone?
Symptom relief Recruiting nowResearchers are comparing two music-based programs to see which may better reduce anxiety in people with advanced cancer. One program pairs participants with a music therapist who uses an AI-powered platform to write songs together. The other has trained staff guide participants …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Oct 16, 2026 00:00 UTC
-
Magic mushroom therapy aims to ease cancer Patients' fear of death
Symptom relief Recruiting nowThis study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) combined with talk therapy can reduce anxiety, depression, and existential distress in people with advanced cancer. Two hundred participants will receive either psilocybin or an active…
Phase 2/3 • Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Oct 16, 2026 00:00 UTC
-
Can a Game-Like AI yoga app help cancer patients rehab at home?
Symptom relief Recruiting nowResearchers at Linkoeping University are co-designing a gamified AI medical yoga app with cancer patients and stakeholders, then testing how feasible and usable it is for home-based rehabilitation. Ten patients undergoing cancer treatment who speak Swedish will use the app for tw…
Sponsor: Linkoeping University • Aim: Symptom relief
Last updated Oct 16, 2026 00:00 UTC
-
New app aims to ease cancer pain at home
Symptom relief Recruiting nowThis study is testing a smartphone app called I-STAMP that helps people with advanced cancer keep track of their pain and medications. About 73 participants will use the app and rate how easy it is to use and how helpful it is. The goal is to see if the app can make managing canc…
Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
New program aims to cut hospital visits by helping cancer patients speak up
Symptom relief Recruiting nowThis trial tests an educational program called A-PACT for people with solid tumors who are at high risk of decline. Trained lay health workers coach patients on how to discuss their care goals and end-of-life wishes with their medical team. The study will see if this reduces unpl…
Sponsor: SWOG Cancer Research Network • Aim: Symptom relief
Last updated Oct 11, 2026 00:00 UTC
-
Can touch and trance together tame Cancer's chronic pain?
Symptom relief Recruiting nowResearchers are testing whether combining osteopathy, a hands-on physical therapy, with therapeutic hypnosis eases chronic pain and emotional distress in cancer patients better than osteopathy alone. The trial enrolls 80 adults with cancer who have had pain for at least three mon…
Sponsor: Institut Rafael • Aim: Symptom relief
Last updated Oct 11, 2026 00:00 UTC
-
AI avatar could help cancer patients remember treatment details
Symptom relief Recruiting nowThis trial tests an AI-powered avatar called ELISA that helps cancer patients learn about their treatment. Patients starting a new cancer therapy often struggle to remember complex information. The avatar provides personalized answers based on approved content. The study compares…
Sponsor: Dr. Mark Mulder • Aim: Symptom relief
Last updated Oct 10, 2026 00:00 UTC
-
New program aims to ease tough End-of-Life talks for cancer patients
Symptom relief Recruiting nowThis study tests a program called ROCKS that helps people with advanced cancer and their family caregivers build optimism, communication skills, and knowledge to discuss advance care planning. 152 patient-caregiver pairs will be randomly assigned to the ROCKS program or usual car…
Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Oct 10, 2026 00:00 UTC
-
Can a phone app help teens with cancer eat better during treatment?
Symptom relief Recruiting nowResearchers are developing and testing MybYte, a smartphone tool that offers personalised nutrition advice to teenagers aged 12 to 18 who are undergoing cancer treatment. In the first phase, about 15 teenagers help refine the tool through interviews and feedback. In the second ph…
Sponsor: KU Leuven • Aim: Symptom relief
Last updated Oct 10, 2026 00:00 UTC
-
New pill aims to stop chemo sickness in its tracks
Symptom relief Recruiting nowThis study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Oct 10, 2026 00:00 UTC
-
Can a Grid-Shaped radiation boost ease symptoms of bulky tumors?
Symptom relief Recruiting nowResearchers are testing whether adding a specialized radiation technique called spatially fractionated radiation therapy (SFRT) to standard palliative radiation helps people with large, inoperable solid tumors feel better. SFRT delivers high doses of radiation in a grid pattern, …
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Oct 09, 2026 00:00 UTC
-
New support program hopes to ease Cancer's toll on chinese patients
Symptom relief Recruiting nowThis study tests a support program for Chinese cancer patients and survivors that includes education sessions, counseling, and peer support. The program is delivered by phone or video call. Researchers want to see if the program is practical and whether it improves quality of lif…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Oct 09, 2026 00:00 UTC
-
Ginseng vs. fatigue: major trial tests natural remedy for cancer patients
Symptom relief Recruiting nowThis Phase III trial tests whether American ginseng can reduce fatigue in 160 cancer patients. Fatigue is a common and tough side effect of cancer and its treatment. Participants will take either ginseng or a placebo, and researchers will measure changes in fatigue levels over ti…
Phase 3 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Oct 08, 2026 00:00 UTC
-
Money worries and cancer: can talking about both ease the burden?
Symptom relief Recruiting nowThis pilot study tests a financial psycho-oncology program for cancer patients facing financial hardship. Participants attend six one-hour sessions over three months that combine emotional support with practical financial education. The study aims to see if the program is feasibl…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Oct 07, 2026 00:00 UTC
-
Home workouts via video calls could ease cancer side effects
Symptom relief Recruiting nowThis study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Oct 04, 2026 00:00 UTC
-
Veterans get paid to quit smoking in new VA study
Symptom relief Recruiting nowThis study tests a program called Contingency Management that gives Veterans rewards for quitting smoking, verified by breath tests. Researchers will first gather feedback from Veterans and staff, then run a small pilot with 20 Veterans over 5 weeks. If successful, a larger trial…
Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Oct 04, 2026 00:00 UTC
-
Nerve grafting may bring back nipple feeling after breast cancer surgery
Symptom relief Recruiting nowThis study looks at whether a nerve graft during nipple-sparing mastectomy can help restore feeling in the nipple. About 20 women with early-stage breast cancer will be randomly assigned to receive the nerve graft or not. The goal is to see if the procedure improves sensation and…
Phase 2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Oct 04, 2026 00:00 UTC
-
New IV combo aims to stop chemo sickness in kids
Symptom relief Recruiting nowChemotherapy often causes nausea and vomiting, which is especially hard for children. This study tests a new IV drug called NEPA (fosnetupitant/palonosetron) to prevent these side effects in kids with cancer. The trial has two parts: first, an open-label phase to find the right d…
Phase 2 • Sponsor: Helsinn Healthcare SA • Aim: Symptom relief
Last updated Oct 01, 2026 00:00 UTC
-
Can a supplement beat cancer fatigue? new trial aims to find out
Symptom relief Recruiting nowThis study tests whether a dietary supplement called Redsenol-1 Plus can safely reduce fatigue in adults who have had cancer treatment. 72 participants will take either the supplement or a placebo for 12 weeks. The main goal is to see if fatigue levels improve, as measured by a s…
Sponsor: Canada Royal Enoch Phytomedicine Co., Ltd. • Aim: Symptom relief
Last updated Sep 30, 2026 00:00 UTC
-
Can Faith-Based counseling ease tough medical choices for cancer patients?
Symptom relief Recruiting nowThis pilot study tests a spiritual care program called PEACE, led by chaplains and clinicians, for people with advanced cancer. The goal is to see if it helps patients whose faith influences their medical decisions. Sixty participants will receive two counseling sessions or usual…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 27, 2026 00:00 UTC
-
Can 4 therapy sessions ease death anxiety in advanced cancer?
Symptom relief Recruiting nowThis study tests a program called Focused Acceptance and Commitment Therapy (FACT) for advanced cancer patients who feel anxious about death. 70 participants will attend four weekly 35-45 minute sessions to learn coping skills. The goal is to see if FACT is safe, acceptable, and …
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 27, 2026 00:00 UTC
-
New study tests coaching to boost Pill-Taking in young cancer patients
Symptom relief Recruiting nowThis study tests whether a tailored coaching program can help adolescents and young adults (ages 15-24) with cancer take their oral medications as prescribed. Participants will work with a coach over four sessions to identify and overcome barriers to adherence, using an electroni…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Symptom relief
Last updated Sep 26, 2026 00:00 UTC
-
New trial aims to ease cancer Patients' breathlessness with tailored oxygen and relaxation techniques
Symptom relief Recruiting nowThis study tests a personalized program called SPOT-ON for cancer patients suffering from severe shortness of breath. Participants will receive a combination of breathing techniques, relaxation methods, posture adjustments, and oxygen-based therapies, either starting early or aft…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 26, 2026 00:00 UTC
-
New study tests simple strategies to help cancer patients regain their sense of taste
Symptom relief Recruiting nowThis study looks at whether teaching cancer patients about taste changes caused by chemotherapy and giving them self-management tools can help reduce those symptoms and maintain healthy eating. About 400 adults starting chemotherapy will be split into two groups: one gets standar…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Sep 26, 2026 00:00 UTC
-
New support program aims to help cancer patients finish treatment and feel better
Symptom relief Recruiting nowThis study tests a program called ICCAN that gives cancer patients extra help with social and economic needs, like finding resources and monthly check-ins. Researchers want to see if this support helps patients complete their cancer treatment and improves their quality of life, c…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 23, 2026 00:00 UTC
-
New surgery showdown: which technique best stops phantom limb pain?
Symptom relief Recruiting nowThis pilot study tests two surgical methods—targeted muscle reinnervation (TMR) and regenerative peripheral nerve interfaces (RPNI)—alone and together to reduce chronic and phantom limb pain in cancer patients who have had an amputation. About 45 adults will be randomly assigned …
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 23, 2026 00:00 UTC
-
Matching cancer survivors to the right level of support
Symptom relief Recruiting nowResearchers at the University of Hong Kong are evaluating a survivorship program that sorts cancer patients into moderate or high needs after treatment. People with moderate needs receive weekly or bi-weekly e-intervention videos on managing distress and weight, with peer volunte…
Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Sep 23, 2026 00:00 UTC
-
Massage during chemo: a new way to fight anxiety?
Symptom relief Recruiting nowThis study tests whether different types of massage can lower anxiety in cancer patients while they receive chemotherapy. Fifty adults who already have high anxiety and are at least one cycle into chemo will receive massage during their infusion sessions. Researchers will measure…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Can zoom therapy ease Cancer's emotional toll? new study tests Meaning-Centered groups
Symptom relief Recruiting nowThis study is testing whether a virtual, 8-session group therapy program can help cancer patients find meaning and reduce emotional distress. Researchers at MD Anderson Cancer Center will enroll 72 adults with a history of cancer. Participants will attend weekly 90-minute session…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New 'Lattice' radiation aims to zap tumor pain better than standard therapy
Symptom relief Recruiting nowThis phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …
Phase 3 • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New shot aims to ease depression and anxiety in cancer and chronic disease patients
Symptom relief Recruiting nowThis study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…
Phase 2 • Sponsor: Reunion Neuroscience Inc • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
AI app aims to boost cancer Patients' mood and quality of life
Symptom relief Recruiting nowThis study tests whether an artificial intelligence (AI) app can improve quality of life, anxiety, and depression in people with cancer who are already receiving psychotherapy. About 60 participants will be randomly assigned to either get the AI app alongside their usual therapy …
Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
New hope for cancer patients suffering from severe diarrhea and colitis from immunotherapy
Symptom relief Recruiting nowThis study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Tailored Pre-Surgery workouts could help seniors with cancer recover faster
Symptom relief Recruiting nowThis pilot study tests a 4-week personalized exercise program for people aged 70 and older who are about to have cancer surgery. Participants follow daily exercises at home using a smartphone app. The goal is to see if this approach improves their physical fitness before the oper…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
New radiation technique aims to ease lung cancer symptoms with fewer side effects
Symptom relief Recruiting nowThis study compares standard palliative radiation for lung tumors with a newer, more focused technique that delivers a higher dose while sparing the esophagus. The goal is to improve or maintain quality of life by better controlling symptoms and reducing side effects. About 141 a…
Sponsor: Chris Goodman • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
New telehealth program aims to ease depression and fatigue in latino cancer patients
Symptom relief Recruiting nowThis study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, tired, or have trouble sleeping. The program is delivered through telehealth (video or phone calls). Researchers want to see if it is practical an…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
New study tests Home-Based exercise and brain games for cancer Survivors' memory woes
Symptom relief Recruiting nowThis pilot study is testing a combined program of mobile health exercise and cognitive rehabilitation for older cancer survivors (age 60+) who have concerns about memory or thinking after treatment. The program uses a smartphone app for exercise tracking and group workshops for b…
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Virtual reality goggles ease pain for kids with cancer
Symptom relief Recruiting nowThis study tests whether using a virtual reality helmet during painful medical procedures (like needle sticks or bone marrow tests) can reduce pain in children with cancer. About 74 children aged 6 to 18 will be split into two groups: one gets standard care plus the VR helmet, th…
Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Magic mushroom therapy targets Cancer-Related depression
Symptom relief Recruiting nowThis phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can a buddy system help older cancer patients? new study says maybe
Symptom relief Recruiting nowThis study tests a 4-month coaching program called SONATA that helps older adults (age 60+) with advanced cancer build a support network of family and friends. The goal is to see if this social support makes it easier to stick with treatment and feel better. About 330 patients an…
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Walking and memory games may boost brain power in older cancer survivors
Symptom relief Recruiting nowThis study tests whether a walking program and cognitive rehabilitation exercises can improve memory and thinking in people aged 65 and older who have finished cancer treatment. Forty participants will be randomly assigned to one of four groups: exercise only, cognitive training …
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can phone Check-Ins ease cancer treatment side effects?
Symptom relief Recruiting nowThis study tests whether regular phone check-ins and counseling can help people on oral cancer drugs feel better and avoid hospital visits. 600 patients will be assigned to symptom monitoring alone, or monitoring plus a self-help handbook and phone counseling for anxiety or sadne…
Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
New online therapy aims to ease cancer Survivors' mental health struggles
Symptom relief Recruiting nowThis study tests an online, therapist-guided program to help cancer survivors who have anxiety, depression, or fear of cancer returning. About 400 adults in Sweden who finished cancer treatment at least 6 months ago will take part. The goal is to see which parts of the 10-week on…
Sponsor: Karolinska Institutet • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can an antidepressant calm Chemotherapy's nerve pain?
Symptom relief Recruiting nowThis trial tests whether duloxetine, a drug commonly used for depression, can reduce the painful nerve damage that some cancer patients experience after receiving taxane chemotherapy. The study enrolls adults with solid tumors who have at least moderate pain from this side effect…
Phase 2 • Sponsor: Yan Yang, MD, Ph.D • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
New Clot-Busting procedure could ease breathing for cancer patients
Symptom relief Recruiting nowThis study looks at whether a computer-assisted vacuum procedure to remove blood clots from the lungs is safe and improves quality of life for cancer patients with a moderate-risk pulmonary embolism. About 25 adults with cancer and a confirmed clot in a major lung artery will tak…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Could a simple activity-based therapy lift depression in older cancer survivors?
Symptom relief Recruiting nowThis study tests whether a short psychotherapy called brief behavioral activation (BBA) can reduce depression and anxiety and improve well-being in older adults who have survived cancer. BBA encourages people to set goals and engage in enjoyable or rewarding activities to change …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Free money for cancer patients: $1,000 monthly cash cards tested in new study
Symptom relief Recruiting nowThis pilot study will give 20 early-stage cancer patients a preloaded cash card with $1,000 each month. The goal is to see if this simple cash support can prevent financial hardship, like debt or missed rent, and improve treatment outcomes. Researchers will measure how many peopl…
Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
A simple talk could ease cancer Patients' anxiety
Symptom relief Recruiting nowThis study tests whether a single early meeting with a psycho-oncology counselor can reduce anxiety and depression and improve quality of life in people recently diagnosed with cancer. About 148 patients will be randomly assigned to either receive this counseling plus standard ca…
Sponsor: Lindenhofgruppe AG • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Cancer care goes home: study tests nurse visits to cut hospital trips
Symptom relief Recruiting nowThis study is testing a new way to manage care for 33 cancer patients who take oral chemotherapy at home. Instead of going to the hospital every month just to pick up medicine, a nurse will visit them at home twice in six months. An advanced practice nurse will coordinate everyth…
Sponsor: Institut Claudius Regaud • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Can a virtual buddy system get older cancer patients moving?
Symptom relief Recruiting nowThis study tests whether a virtual exercise program with peer support helps older adults (60+) with cancer become more active and feel better. Participants are matched with a peer and receive guidance from exercise professionals or just peer support, compared to usual care. Over …
Phase 2/3 • Sponsor: McMaster University • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Heat therapy as a palliative aid: does raising body temperature ease advanced cancer symptoms?
Symptom relief Recruiting nowThis study looks at whether a noninvasive treatment called whole-body infrared hyperthermia can help people with advanced solid tumors feel better. The therapy uses infrared energy to raise body temperature in a controlled way, and researchers will track changes in pain, fatigue,…
Sponsor: Zhejiang Hospital • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
Digital brain training may ease 'chemo brain' — a trial puts it to the test
Symptom relief Recruiting nowThis trial tests whether two types of home-based digital cognitive training can help cancer survivors who have memory, attention, or thinking problems after chemotherapy. Participants will use either a computer program (BrainHQ) or a virtual reality cognitive training for 10 week…
Sponsor: Biogipuzkoa Health Research Institute • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Digital navigator aims to cut financial toxicity for young adults with cancer
Symptom relief Recruiting nowThis pilot study tests a hybrid intervention that combines a digital platform (Findhelp.org) with human navigation sessions to help adolescent and young adult cancer survivors manage financial and health-related social needs. Researchers will refine the approach with input from s…
Sponsor: Columbia University • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Could a homeopathic remedy ease cancer treatment fatigue?
Symptom relief Recruiting nowThis study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…
Early phase 1 • Sponsor: Beaura for Para Pharmaceutical Products Trading LLC • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Spinal pain pump may offer relief for cancer patients when opioids fail
Symptom relief Recruiting nowThis trial tests whether a small pump implanted in the abdomen that delivers pain medicine directly to the spinal fluid can improve quality of life for people with severe cancer pain that is not controlled by oral opioids. Participants are randomly assigned to get the pump or to …
Sponsor: Universitair Ziekenhuis Brussel • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Weighted blankets may ease anxiety for cancer patients during IV therapy
Symptom relief Recruiting nowThis study looks at whether using a weighted blanket during intravenous cancer treatment can help lower anxiety, stress, and depression, and improve comfort. About 152 adults with solid cancers who are starting their first IV therapy will be randomly assigned to receive either a …
Sponsor: Sultan Qaboos Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Could a nurse-led online therapy beat severe fatigue in advanced cancer?
Symptom relief Recruiting nowThis trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New online tool aims to lift mood in cancer patients
Symptom relief Recruiting nowThis study tests an online program called My Wellbeing Guide for cancer patients who feel depressed or anxious. The program uses videos, activities, and written tips based on cognitive behavioral therapy over 7 weeks. About 6,500 participants will be randomly assigned to the prog…
Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New program aims to remove travel hurdles for cancer patients
Symptom relief Recruiting nowThis study tests a program called TRACT that helps cancer patients with travel to their radiation therapy appointments. Many patients miss or delay treatment due to transportation issues. The program provides navigation support and resources. Researchers will see if it is practic…
Sponsor: Emory University • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Kidney shield? new trial tests citrus compound for chemo patients
Symptom relief Recruiting nowThis study tests whether a combination of diosmin and hesperidin, natural compounds found in citrus fruits, can protect the kidneys of cancer patients receiving platinum-based chemotherapy. One hundred adults with confirmed cancer will take the supplement alongside their chemo to…
Phase 4 • Sponsor: Beni-Suef University • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Home workouts with live coaching could ease cancer side effects
Symptom relief Recruiting nowThis study tests whether a 12-week personalized exercise program, done at home with a trainer guiding via video, can improve quality of life and reduce common side effects like fatigue, anxiety, and nerve pain in cancer survivors. About 350 adults who finished cancer treatment wi…
Sponsor: UMC Utrecht • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Card game aims to ease tough End-of-Life talks for cancer patients
Symptom relief Recruiting nowThis study tests whether a simple card game, the Go Wish Game, can help people with advanced blood cancers or solid tumors discuss their end-of-life priorities with doctors. About 75 patients will use the cards to sort what matters most to them, then complete an advance care plan…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Virtual therapy aims to tame Cancer's behavioral toll on kids
Symptom relief Recruiting nowThis study tests whether an internet-based parent-child interaction therapy (I-PCIT) can help improve behavior in children aged 2-12 who have or had cancer. Parents of 300 children will be randomly assigned to start therapy right away or wait 5-6 months. The goal is to see if the…
Sponsor: Johns Hopkins All Children's Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:27 UTC
-
New study aims to help cancer patients and families avoid crises with early coaching calls
Symptom relief Recruiting nowThis study tests a program called ENABLE-SG, which provides phone-based coaching sessions to people recently diagnosed with advanced cancer and their caregivers. The goal is to help them manage stress, symptoms, and planning early on, rather than waiting for a crisis. Researchers…
Sponsor: National Cancer Centre, Singapore • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
New study tests if checking in from home can improve cancer care
Symptom relief Recruiting nowThis study tests a program where cancer patients report symptoms from home using a digital questionnaire. A nurse monitors the results and provides advice between clinic visits. The goal is to see if this improves quality of life and reduces emergency room visits and hospital sta…
Sponsor: University of Calgary • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Virtual reality may ease chemo brain in cancer survivors
Symptom relief Recruiting nowThis study tests whether immersive virtual reality (VR) exercises can improve memory, attention, and thinking speed in people with cancer who have mental fogginess after chemotherapy. Sixty participants will either use VR-based cognitive, physical, and mindfulness training or do …
Sponsor: Consorci Sanitari de Terrassa • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Magic mushroom compound tested as One-Time depression fix for cancer patients
Symptom relief Recruiting nowThis study tests whether a single 25 mg dose of psilocybin can relieve major depression in 100 adults with cancer, compared to a very low 1 mg dose. Participants must be 20–80 years old, have had depression for at least a month after their cancer diagnosis, and stop other antidep…
Phase 2 • Sponsor: Section for Affective Disorders; Northern Stockholm Psychiatry • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Scientists gather tumor samples to unlock new cancer treatments
Knowledge-focused Recruiting nowThis study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Scientists hunt for hidden cancer clues in families
Knowledge-focused Recruiting nowThis study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Cancer tissue bank opens to fuel research
Knowledge-focused Recruiting nowThis study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
New program aims to bridge cancer care gaps for native americans
Knowledge-focused Recruiting nowThis study is testing a program to help Native American cancer patients get better coordinated care. It brings together a cancer center and tribal health systems to improve communication and support. About 187 adults newly diagnosed with cancer will take part. The goal is to see …
Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
New tool helps young cancer survivors navigate fertility choices
Knowledge-focused Recruiting nowThis study tests a fertility preservation decision aid for young cancer survivors and their parents. The goal is to see if the tool helps them better understand fertility status and future parenthood options. About 358 participants will be randomly assigned to receive either the …
Sponsor: Murdoch Childrens Research Institute • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Cancer data pooling study aims to connect the dots across trials
Knowledge-focused Recruiting nowThis study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Mayo clinic launches massive genetic study to unlock cancer secrets
Knowledge-focused Recruiting nowThis study aims to find markers and causes of cancer by analyzing participants' DNA, RNA, and tissue samples. Researchers will use this information to improve cancer prevention, early detection, and treatment. The study will enroll 500 adults with cancer at Mayo Clinic.
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Radiation aftermath: 700 cancer patients tracked for decades
Knowledge-focused Recruiting nowThis study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
New trial uses DNA tests to match cancer patients to targeted drug cocktails
Knowledge-focused Recruiting nowThis large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Cancer registry aims to match tumor genes to targeted drugs
Knowledge-focused Recruiting nowResearchers at the Medical College of Wisconsin run an observational registry for adults who receive care for a cancer-related condition. The registry collects medical data and biospecimens, both from past records and from samples given during the study. The goal is to study how …
Sponsor: Sameem M. Abedin, MD • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Tracking childhood cancer survivors for decades to improve their future health
Knowledge-focused Recruiting nowThis long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Study explores how medical info delivery shapes cancer care decisions
Knowledge-focused Recruiting nowThis study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
New study checks cancer Drug's effect on common medications
Knowledge-focused Recruiting nowThis study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Scientists hunt for cancer clues in blood, urine, and bone marrow
Knowledge-focused Recruiting nowThis study collects samples from 320 people, including those with solid cancers (like lung, colon, or pancreatic cancer) and those undergoing lung cancer screening, to look for cancer cells and DNA in blood, urine, and bone marrow. The goal is to learn how cancer spreads and find…
Sponsor: University of Missouri-Columbia • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Can lab tests unlock hidden cancer drug options?
Knowledge-focused Recruiting nowThis study looks at whether special tests can predict which off-guideline drugs—FDA-approved for other cancers but not for a patient's specific cancer—might work for them. It involves 300 advanced cancer patients whose doctors are willing to try these drugs. The goal is to see ho…
Sponsor: Cancer Commons • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
Gene-Matching trial aims to outsmart cancer by pairing mutations with drugs
Knowledge-focused Recruiting nowThis study is analyzing tumor and blood samples from 10,000 adults with advanced solid tumors or blood cancers to find genetic changes that can be targeted by existing drugs. The goal is to see how often these 'actionable' alterations occur and to guide patients toward personaliz…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
Can muscle wasting predict who suffers worst from chemo?
Knowledge-focused Recruiting nowResearchers are tracking 700 adults with solid tumors who are starting systemic anti-cancer treatment. The study measures body composition with bioimpedance and muscle performance with grip strength and chair-rise tests, plus activity trackers, to see whether sarcopenia predicts …
Sponsor: Centre Hospitalier Metropole Savoie • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
Massive cancer gene database aims to match tumors to future treatments
Knowledge-focused Recruiting nowResearchers are building a large registry of genomic, molecular, and clinical information from people with suspected or confirmed cancer. Participants provide tumor sequencing data and allow the team to follow their treatment and outcomes over time. The goal is to discover gene a…
Sponsor: BostonGene • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
Can a video call help older cancer patients get better care?
Knowledge-focused Recruiting nowThis study looks at whether a special health check-up done over video (telemedicine) can help find weak spots in older adults with cancer and guide their care. It includes 216 people aged 65 and older with cancer who are starting a new treatment. The goal is to see if this approa…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
New screening tool aims to spot cancer survivors who need help with daily tasks
Knowledge-focused Recruiting nowThis study is testing a new questionnaire called SOCS-OTS to see if it can correctly identify cancer survivors who need occupational therapy. Researchers at MD Anderson will compare it to a standard screening tool in 80 adults. The goal is to make sure the new tool accurately fin…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Oct 08, 2026 00:00 UTC
-
Can a scan predict radiation harm to heart and lungs?
Knowledge-focused Recruiting nowThis study is looking for early signs of heart and lung damage in people receiving radiation for chest cancers. Researchers will use PET/MR scans and blood tests before and after treatment to see if they can predict who will develop problems like pulmonary hypertension. The goal …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Oct 07, 2026 00:00 UTC
-
Scientists investigate why immunotherapy causes autoimmune problems in some cancer patients
Knowledge-focused Recruiting nowThis study aims to understand why some cancer patients develop autoimmune side effects when treated with immune checkpoint inhibitors. Researchers will analyze blood cells and genetics from 600 participants to identify features linked to these side effects. The goal is to improve…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Oct 07, 2026 00:00 UTC
-
New biobank aims to unlock secrets of Immunotherapy's harsh side effects
Knowledge-focused Recruiting nowThis study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Oct 07, 2026 00:00 UTC
-
Chatbot vs. standard care: which boosts genetic testing in young cancer patients?
Knowledge-focused Recruiting nowThis study tests whether a digital chatbot can help more adolescents and young adults (AYA) with cancer get genetic counseling and testing compared to standard remote services. About 535 participants aged 18-39 will use either a chatbot or standard telehealth. The goal is to see …
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Oct 04, 2026 00:00 UTC
-
Breast cancer subtypes may hold clues to survival and cost
Knowledge-focused Recruiting nowResearchers in Bogota, Colombia, are reviewing the medical records of 370 women treated for breast cancer between 2014 and 2024. They want to see how different molecular subtypes of the disease relate to survival, recurrence, treatment response, and side effects. The study also l…
Sponsor: Fundación Santa Fe de Bogota • Aim: Knowledge-focused
Last updated Oct 04, 2026 00:00 UTC
-
Can exercise boost brain power in young cancer survivors?
Knowledge-focused Recruiting nowThis study explores the link between physical activity and thinking skills in people who survived cancer as adolescents or young adults. Researchers will use computer-based brain games to measure memory and attention. The goal is to understand how exercise might help brain health…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Oct 04, 2026 00:00 UTC
-
Can a urine test reveal when the end of life is near?
Knowledge-focused Recruiting nowResearchers are collecting weekly urine samples from adults with solid tumor cancers to look for metabolic changes that occur as death approaches. The study aims to understand the biology of dying and explore whether a test could one day predict the last days or weeks of life. Be…
Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust • Aim: Knowledge-focused
Last updated Oct 02, 2026 00:00 UTC
-
New cancer trial aims to crack the code of who benefits from immunotherapy
Knowledge-focused Recruiting nowThis study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…
Phase 2 • Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Oct 01, 2026 00:00 UTC
-
Massive global study aims to uncover why young cancer patients in poorer nations fare worse
Knowledge-focused Recruiting nowThis study will follow 6,000 children, adolescents, and young adults with cancer in low- and middle-income countries. Researchers will collect data from medical records and questionnaires to understand why treatment failure and severe side effects are more common in these setting…
Sponsor: Resonance, Inc. • Aim: Knowledge-focused
Last updated Oct 01, 2026 00:00 UTC
-
Can your smartphone help fight cancer? new study aims to find out
Knowledge-focused Recruiting nowThis study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Oct 01, 2026 00:00 UTC
-
Massive study tracks radiation therapy results to improve cancer care
Knowledge-focused Recruiting nowThis study is collecting information from up to 40,000 cancer patients who are receiving radiation therapy. Researchers will track their outcomes to better understand what works and how to reduce side effects. The goal is to improve patient care by learning from real-world treatm…
Sponsor: Proton Collaborative Group • Aim: Knowledge-focused
Last updated Oct 01, 2026 00:00 UTC
-
Cutting pills, not hope: study probes cancer Patients' views on deprescribing
Knowledge-focused Recruiting nowThis study looks at how people with advanced cancer feel about stopping or reducing medications that may no longer help. Researchers will interview about 25 patients and survey 300 more to understand their attitudes and beliefs. The goal is to learn what factors influence their v…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Sep 27, 2026 00:00 UTC
-
Blood test may predict dangerous side effects of cancer immunotherapy
Knowledge-focused Recruiting nowThis observational study is looking at whether certain markers in the blood can predict immune-related side effects in cancer patients receiving immunotherapy. Researchers will collect blood samples and health data from 200 participants during routine visits. The goal is to bette…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Sep 27, 2026 00:00 UTC
-
AI chatbot aims to ease financial burden for rural cancer patients
Knowledge-focused Recruiting nowThis study tests a new chatbot designed to help cancer patients and their caregivers in rural areas find clear information about insurance, travel costs, and other financial aspects of cancer care. About 60 participants will be randomly assigned to use either a hybrid chatbot or …
Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Sep 27, 2026 00:00 UTC
-
Cancer blood test research launches at princess margaret
Knowledge-focused Recruiting nowThis study aims to create a large collection of blood samples from 2,500 people with or at high risk for cancer. Researchers will use these samples to study liquid biopsies, which are blood tests that may help detect cancer, track treatment response, and spot recurrence. Particip…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Sep 27, 2026 00:00 UTC
-
Cancer genes under the microscope: study seeks to unlock personalized treatments
Knowledge-focused Recruiting nowThis study looks at the genes in cancer tumors to find mutations that might be important for how the cancer grows. Researchers will use leftover tissue from surgeries or biopsies, along with a blood or saliva sample, to compare cancer genes to normal genes. The goal is to underst…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Sep 26, 2026 00:00 UTC
-
4D MRI scans could reveal hidden clues about heart disease and cancer
Knowledge-focused Recruiting nowThis study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…
Sponsor: Ulsan University Hospital • Aim: Knowledge-focused
Last updated Sep 25, 2026 00:00 UTC
-
Fitbits and iPhones used to predict hospitalizations in cancer patients
Knowledge-focused Recruiting nowThis study is testing whether wearable activity trackers like Fitbits and iPhones can help predict when cancer patients undergoing radiation therapy might need emergency care or hospitalization. Researchers will collect step counts and other health data from 260 participants to b…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 25, 2026 00:00 UTC
-
New tech aims to bridge cancer care gap for vulnerable patients
Knowledge-focused Recruiting nowThis study will test a remote monitoring platform designed to help cancer patients who face barriers like language or lack of insurance. About 50 adults with cancer will use the platform at home to track symptoms and communicate with their care team. The goal is to see if the pla…
Sponsor: VERIS HEALTH INC • Aim: Knowledge-focused
Last updated Sep 25, 2026 00:00 UTC
-
Can a simple BMI reading predict quality of life for cancer patients?
Knowledge-focused Recruiting nowResearchers are studying whether body mass index (BMI) is linked to health-related quality of life in people with solid tumors. The trial includes about 1,380 adults with a confirmed solid tumor diagnosis. Participants complete standard quality-of-life questionnaires, and researc…
Sponsor: University of Rome Tor Vergata • Aim: Knowledge-focused
Last updated Sep 25, 2026 00:00 UTC
-
Gene therapy survivors monitored for years in massive safety study
Knowledge-focused Recruiting nowThis study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…
Phase 2/3 • Sponsor: Celgene • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study checks how liver issues affect cancer drug pelabresib
Knowledge-focused Recruiting nowThis early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Cancer care at home: what do patients and doctors really think?
Knowledge-focused Recruiting nowThis study interviews cancer care providers, patients, and caregivers to learn their thoughts and feelings about receiving hospital-level care at home. The goal is to understand what people know and believe about home hospital care, so that future programs can be designed to bett…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study aims to make cancer trials fairer for minorities
Knowledge-focused Recruiting nowThis study tests whether a video and personal guidance can help Black, Latinx, and older adults with cancer get genetic testing. Genetic testing is often needed to join precision cancer trials. The goal is to make trial enrollment more equitable. About 210 people with gastrointes…
Sponsor: Nadine Jackson, MD, MPH • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
AI aims to speed up cancer trial enrollment for 70,000 patients
Knowledge-focused Recruiting nowThis study is building an AI tool called ACTIVATE that scans electronic health records to find cancer patients who may be eligible for clinical trials. Researchers will test whether sending alerts to doctors increases the number of patients starting trials. The goal is to make it…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can science predict cancer fatigue? new study seeks answers
Knowledge-focused Recruiting nowThis study tracks 125 cancer patients receiving standard chemotherapy and radiation to understand why they feel tired. Researchers will collect blood, stool, and survey data before, during, and after treatment. The goal is to find patterns that could help predict and manage fatig…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New tool aims to bridge the gap in cancer conversations
Knowledge-focused Recruiting nowThis study tests a communication tool called TrialTalk™ in cancer clinics. The goal is to see if it helps doctors and patients talk more clearly about treatment options. About 30 patients and their doctors will fill out questionnaires before and after a regular visit. The study f…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New program aims to boost clinical trial awareness among minorities
Knowledge-focused Recruiting nowThis study is testing an educational program designed to help racial and ethnic minority cancer patients make informed decisions about joining clinical trials. The program involves watching short videos and talking with a patient navigator. Researchers will measure changes in pat…
Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can remote training bring better cancer care to underserved communities?
Knowledge-focused Recruiting nowThis study tests whether a telementoring program called ECHO can improve the quality of palliative care for advanced cancer patients in underserved areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia. Researchers will train local doctors through online clinics and w…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
New toolkit aims to fix cancer trial diversity gap
Knowledge-focused Recruiting nowThis study tests a program called SUPPORT that helps Black and Latino cancer patients learn about and join clinical trials. The program includes a website and a navigator who guides patients. Researchers will see if this increases the number of patients referred to and enrolled i…
Sponsor: Eastern Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Can special heart checkups protect cancer patients from their own treatment?
Knowledge-focused Recruiting nowSome cancer drugs cause rare but serious heart and metabolic problems. This study follows 5,000 cancer patients across several French hospitals who receive a dedicated heart checkup and ongoing follow-up through cardio-oncology programs. Researchers track how many patients benefi…
Sponsor: Groupe Hospitalier Pitie-Salpetriere • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
EU-Wide survey aims to uncover hidden gaps in mental health support for cancer patients
Knowledge-focused Recruiting nowThis study uses online surveys to explore whether cancer patients and their family members across the European Union have equal access to mental health screening and psychological support. Researchers will analyze responses from 2,000 participants to identify disparities, barrier…
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
What do you risk for a chance at remission? cell therapy survey asks
Knowledge-focused Recruiting nowCell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…
Sponsor: Zhejiang University • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Chemo ear damage worse for poorer patients, study warns
Knowledge-focused Recruiting nowThis study looks at how platinum-based chemotherapy can cause permanent hearing loss in cancer patients, and whether people from poorer backgrounds are more affected. Researchers will test hearing and thinking skills in 172 patients from North West England before and after treatm…
Sponsor: Lancaster University • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Do men and women react differently to immunotherapy? new study aims to find out
Knowledge-focused Recruiting nowThis study looks at whether men and women experience different side effects from cancer immunotherapy. Researchers will track symptoms and quality of life in 100 adults starting standard immunotherapy. The goal is to better understand how sex and gender influence treatment experi…
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
New study aims to reduce bleeding and clotting risks in cancer surgery patients on blood thinners
Knowledge-focused Recruiting nowThis study follows 700 cancer patients who take blood thinners and are scheduled for surgery or medical procedures. Researchers will track how often major bleeding or clotting events occur within 30 days after the procedure. The goal is to see if current blood thinner management …
Sponsor: Ottawa Hospital Research Institute • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Blood biomarkers may predict cancer treatment side effects
Knowledge-focused Recruiting nowThis pilot study investigates whether certain molecules in the blood, called miRNAs and proteins, change during cancer treatment and whether these changes can signal early signs of heart or lung damage. Researchers will compare blood samples from patients receiving radiation or c…
Sponsor: University Hospitals Coventry and Warwickshire NHS Trust • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Money for travel and childcare may open cancer trials to more people
Knowledge-focused Recruiting nowThis study looks at whether offering money for things like travel, lodging, and childcare helps more people from different backgrounds join cancer clinical trials. Researchers will track enrollment and retention of 1,200 patients who are already in a cancer trial. They will compa…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Tracking infection markers over time may spot sepsis sooner in cancer patients
Knowledge-focused Recruiting nowThis study tests whether tracking changes in infection markers and blood culture results over time can help detect sepsis earlier and monitor treatment in adults with cancer. Researchers will follow 100 patients with suspected sepsis during their hospital stay and for up to 30 da…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
New imaging registry aims to sharpen cancer treatment precision
Knowledge-focused Recruiting nowThis study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …
Sponsor: Mark C Burgmans, MD PhD • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Can a simple screening help cancer patients get mental health support?
Knowledge-focused Recruiting nowThis study tests a program that screens cancer patients for emotional distress and refers them to mental health services if needed. It involves 50 English- or Spanish-speaking adults with new solid tumor cancers at Jamaica Hospital Medical Center. The goal is to see if such a pro…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Could a workout after cancer treatment help you live longer?
Knowledge-focused Recruiting nowThis study looks at whether exercise after finishing cancer treatment is linked to better outcomes, like longer survival without the cancer coming back. Researchers will analyze data from 1,000 adult cancer survivors at Memorial Sloan Kettering. The goal is to see if those who ex…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Yale launches massive blood repository to unlock cancer secrets
Knowledge-focused Recruiting nowThis study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Can 3D-Printed molds pinpoint cancer hotspots?
Knowledge-focused Recruiting nowThis trial tests whether 3D-printed molds, created from radiological images, can guide pathologists to sample the most informative parts of a removed tumor. Currently, sampling is done by eye, which may miss key regions. The study will compare samples taken with the mold to stand…
Sponsor: Tampere University Hospital • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Can we predict dangerous side effects when combining radiation and immunotherapy?
Knowledge-focused Recruiting nowThis study is a large registry that tracks cancer patients who receive both radiotherapy and molecular therapies, such as immunotherapy. The goal is to better understand how these two treatments interact and to identify how often severe side effects occur. By collecting data from…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Tumor DNA mapping may unlock personalized cancer therapies
Knowledge-focused Recruiting nowThis study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…
Sponsor: Ulrik Lassen • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
AI platform aims to unlock Real-World cancer data on a massive scale
Knowledge-focused Recruiting nowThis study enrolls people diagnosed with cancer to build a large registry using Olivia, an AI-powered health platform. The platform will collect and combine electronic health records and patient-reported outcomes from over 1,000 healthcare systems. The goal is to create a compreh…
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New study aims to bridge psychosocial care gap for cancer survivors
Knowledge-focused Recruiting nowThis study tests whether a routine digital screening followed by a supportive phone call can help cancer survivors get the emotional and social support they need after finishing primary treatment. Fifty adults who have completed cancer therapy will take part. The goal is to see i…
Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Can modern Radiotherapy's late effects be predicted?
Knowledge-focused Recruiting nowThis study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Reading Cancer's genetic playbook: a quest to match patients to the right experimental therapy
Knowledge-focused Recruiting nowThis observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…
Sponsor: Institute of Cancer Research, United Kingdom • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can chemo and radiation steal fertility? a massive study aims to find out
Knowledge-focused Recruiting nowThis observational study tracks 7,000 men and women with cancer to see how treatments like chemotherapy, radiation, and immunotherapy affect fertility. In women, researchers measure a hormone called AMH to gauge ovarian reserve; in men, they analyze sperm quality. The goal is to …
Sponsor: Michael von Wolff • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
Rare cancer in pregnancy: global registry aims to fill knowledge gap
Knowledge-focused Recruiting nowThis international registry collects data on patients diagnosed with thoracic cancers (including lung cancer) while pregnant or who become pregnant during or after cancer treatment. Because these cases are rare, there is little information to guide doctors. The registry aims to d…
Sponsor: Oncology Institute of Southern Switzerland • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
New approach aims to make repeat radiation safer for cancer patients
Knowledge-focused Recruiting nowThis study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…
Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Cancer Patients' supplement use under the microscope
Knowledge-focused Recruiting nowThis observational study will survey 1,000 cancer patients about their use of dietary supplements like vitamins, minerals, and herbal products. Researchers want to know how common supplement use is, whether patients experience side effects, and if these supplements could interact…
Sponsor: Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New italian tool aims to ease MRI anxiety for cancer patients
Knowledge-focused Recruiting nowThis study is translating and testing an Italian version of a questionnaire that measures anxiety in cancer patients during whole-body MRI scans. Researchers will enroll 175 adult cancer patients at the European Institute of Oncology. The goal is to ensure the Italian version is …
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Massive cancer study aims to unlock tumor secrets and speed up trials
Knowledge-focused Recruiting nowSPECTA is a large research platform that collects tumor samples, genetic data, and patient information from nearly 5,000 people with all types of cancer. The goal is to help scientists better understand cancer biology and find new ways to match patients with the right clinical tr…
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New PET imaging study aims to sharpen tumor detection
Knowledge-focused Recruiting nowThis study is collecting data from 2,000 adults with solid tumors who undergo theranostic PET scans as part of their routine care. The goal is to see how well these scans detect tumors and match with lab results, which could help doctors make better treatment decisions. Participa…
Sponsor: University Hospital, Essen • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Decoding Immunotherapy's liver side effect to keep cancer treatment on track
Knowledge-focused Recruiting nowThis study looks at liver inflammation (hepatitis) that can occur in cancer patients treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers aim to describe the different patterns of liver injury and how they respond to treatment. By collecting real-world …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study aims to unravel cancer blood clot mysteries
Knowledge-focused Recruiting nowThis study is collecting blood and urine samples from 150 cancer patients who have had blood clots. The goal is to learn more about why clots happen in cancer and how to prevent them. Participants will be followed over time to track clot recurrence and bleeding risks.
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists probe immune resistance in tumors to outsmart cancer
Knowledge-focused Recruiting nowThis study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
500 cancer patients join quest to unlock precision medicine secrets
Knowledge-focused Recruiting nowThis study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Blood biopsy study aims to improve cancer detection and monitoring
Knowledge-focused Recruiting nowThis study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
10,000 cancer patients join ontario Gene-Mapping effort to personalize care
Knowledge-focused Recruiting nowThis study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
40,000 cancer patients join quest for biomarkers
Knowledge-focused Recruiting nowThis study aims to build a large biobank of blood samples from 40,000 cancer patients to help identify biomarkers that can predict survival and response to treatment. Participants provide an extra 36ml of blood during routine blood draws. The samples will be used in future resear…
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Personalized cancer care: DNA profiling guides patients to best trials
Knowledge-focused Recruiting nowThis study analyzes the DNA of solid tumors from 5,500 cancer patients to find genetic changes that could be targeted by specific treatments. The goal is to use this molecular profile to match patients with appropriate clinical trials. Participants must have a confirmed solid tum…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Can Off-Label drugs help when standard cancer therapy fails? new study aims to find out
Knowledge-focused Recruiting nowThis study is for people with advanced solid tumors who have run out of standard treatment options. Researchers will track how well off-label or non-standard therapies work when chosen based on the tumor's genetic profile. The goal is to create a standard way to measure responses…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Can what you eat during cancer treatment change your survival?
Knowledge-focused Recruiting nowThis study follows 1,538 cancer patients in China to see how their nutritional status affects how well they handle chemotherapy and radiation, their quality of life, and how long they live. Researchers will track changes in diet, weight, and blood markers over time. The goal is t…
Sponsor: Xiaoqin Luo • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New registry aims to uncover how cancer ages young bodies
Knowledge-focused Recruiting nowThis study is building a registry of 500 children, teens, and young adults (ages 1-39) diagnosed with cancer. Participants will complete physical and mental function tests, surveys, and provide blood samples over time. The goal is to learn how cancer and its treatments affect agi…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Your genes could guide your pain meds: new study tests personalized prescribing
Knowledge-focused Recruiting nowThis study looks at whether giving doctors genetic information about their patients can help them choose safer and more effective pain medications. Researchers will enroll 800 cancer patients who are expected to need opioid painkillers. Half will have their genes tested to guide …
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists hunt for Cancer-Fighting immune cells in patients
Knowledge-focused Recruiting nowThis study is collecting blood samples from 300 cancer patients to look for immune cells that target tumors. Researchers want to understand how the immune system responds to cancer and treatments. The study does not test a new drug or therapy, but aims to gather knowledge that co…
Sponsor: Institut Curie • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New program aims to ease tough transition for older cancer patients
Knowledge-focused Recruiting nowThis study tests a program called ALIGN, which uses palliative care social workers and patient navigators to support older adults with advanced cancer who are moving from the hospital to a skilled nursing facility. The goal is to see if the program is practical and can help align…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Cancer patients rate their care in new satisfaction study
Knowledge-focused Recruiting nowThis study looks at how satisfied cancer patients are after a special team assessment in a day hospital. About 309 adults with cancer will fill out a questionnaire after meeting with a pharmacist, dietitian, psychologist, social worker, and other care providers. The goal is to fi…
Sponsor: Centre Hospitalier de Martigues • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
10,000 patients join massive chest tumor data drive
Knowledge-focused Recruiting nowThis study is gathering information from 10,000 people with lung cancer or other chest tumors. Researchers want to learn more about the disease, how it is treated, and what affects a person's outlook. No new treatments are being tested—the goal is to collect data to help improve …
Sponsor: Spanish Lung Cancer Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Your story matters: new study seeks cancer patients and caregivers to share experiences
Knowledge-focused Recruiting nowThis study uses online surveys to learn about the real-life experiences of people diagnosed with cancer and their caregivers. Researchers want to understand the emotional, physical, social, and financial challenges they face. The goal is to use this information to improve support…
Sponsor: Cancer Support Community, Research and Training Institute, Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Statin-Free in palliative care: could stopping cholesterol drugs improve quality of life?
Knowledge-focused Recruiting nowThis study looks at whether it is safe and beneficial for people with advanced cancer to stop taking statins, which are cholesterol-lowering drugs often used for prevention. Researchers will follow 80 patients in palliative care for 12 weeks, monitoring cholesterol levels, muscle…
Sponsor: Stiftelsen Stockholms Sjukhem • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
What teens write about cancer could change how hospitals help
Knowledge-focused Recruiting nowThis study collects and analyzes personal writings from 500 teenage cancer patients to understand their emotions and experiences. The goal is to improve communication between patients and healthcare providers and make hospital care more supportive. No new drugs or treatments are …
Sponsor: Centro di Riferimento Oncologico - Aviano • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
AI translates doctor speak for cancer patients
Knowledge-focused Recruiting nowThis study tests whether using artificial intelligence (AI) to rewrite medical discharge letters into plain language helps cancer patients better understand their diagnosis, treatment, and next steps. About 150 adults with blood cancer or other cancers will be randomly assigned t…
Sponsor: Technical University of Munich • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Heart MRI spots chemo damage before It's too late
Knowledge-focused Recruiting nowThis study tests whether special heart MRI scans can find early signs of heart damage in cancer patients getting anthracycline chemotherapy. Current tests often miss this damage until it's advanced. About 93 adults will get several MRI scans before, during, and after treatment. T…
Sponsor: Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New tool to measure cancer Patients' Pre-Surgery fears
Knowledge-focused Recruiting nowThis study aims to validate a questionnaire that measures anxiety in cancer patients before surgery. Researchers will test the Italian version of the Surgical Anxiety Questionnaire (SAQ) with 180 adult patients. The goal is to better understand patients' fears and concerns so tha…
Sponsor: Centro di Riferimento Oncologico - Aviano • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC